mirror of
https://github.com/gladstone-institutes/Bioinformatics-Workshops.git
synced 2025-11-30 09:45:43 -08:00
74 KiB
74 KiB
| 1 | set_id | name | ID | Name | Size | Coverage | TDP.bound | TDP.estimate | SC.adjP | Comp.adjP |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 | WP1600 | Nicotine Metabolism | 38 | WP1600 | 6 | 0.17 | 1 | 1 | 3.39506009152496e-24 | 3.39506009152496e-24 |
| 3 | WP2276 | Glial Cell Differentiation | 88 | WP2276 | 8 | 0.62 | 0.4 | 0.4 | 7.83386153710323e-26 | 5.70447887867626e-23 |
| 4 | WP4030 | SCFA and skeletal muscle substrate metabolism | 332 | WP4030 | 6 | 0.33 | 0.5 | 0.5 | 7.99040804992212e-20 | 7.99040804992212e-20 |
| 5 | WP334 | GPCRs, Class B Secretin-like | 210 | WP334 | 24 | 0.17 | 0.5 | 0.5 | 3.06579274689702e-21 | 1.60955895014834e-18 |
| 6 | WP1991 | SRF and miRs in Smooth Muscle Differentiation and Proliferation | 60 | WP1991 | 13 | 0.69 | 0.888888888888889 | 1 | 5.37258163429194e-24 | 1.16900918682e-14 |
| 7 | WP206 | Fatty Acid Omega Oxidation | 76 | WP206 | 15 | 0.33 | 0.6 | 0.8 | 2.94021006969881e-38 | 1.31928124608757e-14 |
| 8 | WP3299 | let-7 inhibition of ES cell reprogramming | 205 | WP3299 | 15 | 0.33 | 0.6 | 0.6 | 1.69191698398203e-15 | 1.74501293167954e-14 |
| 9 | WP2023 | Cell Differentiation - Index expanded | 66 | WP2023 | 50 | 0.22 | 0.727272727272727 | 0.727272727272727 | 4.7856489956754e-16 | 2.33586928012365e-14 |
| 10 | WP2029 | Cell Differentiation - Index | 67 | WP2029 | 42 | 0.14 | 0.833333333333333 | 0.833333333333333 | 4.7856489956754e-16 | 2.33586928012365e-14 |
| 11 | WP2366 | Butyrate-induced histone acetylation | 105 | WP2366 | 2 | 1 | 0.5 | 0.5 | 1.10524321914212e-13 | 1.10524321914212e-13 |
| 12 | WP3297 | EV release from cardiac cells and their functional effects | 203 | WP3297 | 9 | 0.44 | 0.75 | 0.75 | 3.05550468161626e-32 | 3.37870774082303e-13 |
| 13 | WP554 | ACE Inhibitor Pathway | 530 | WP554 | 17 | 0.65 | 0.545454545454545 | 0.545454545454545 | 3.79036700534385e-25 | 5.54255202240522e-13 |
| 14 | WP4284 | Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer | 385 | WP4284 | 5 | 0.4 | 0.5 | 0.5 | 2.90591396510707e-11 | 2.90591396510707e-11 |
| 15 | WP2361 | Gastric Cancer Network 1 | 103 | WP2361 | 29 | 0.76 | 0.727272727272727 | 0.727272727272727 | 3.61848623532521e-17 | 1.04514067941364e-10 |
| 16 | WP3944 | Serotonin and anxiety-related events | 309 | WP3944 | 13 | 0.46 | 0.666666666666667 | 0.666666666666667 | 1.45750470372243e-17 | 3.26510400891469e-09 |
| 17 | WP3947 | Serotonin and anxiety | 311 | WP3947 | 17 | 0.41 | 0.428571428571429 | 0.428571428571429 | 1.45750470372243e-17 | 3.26510400891469e-09 |
| 18 | WP1438 | Influenza A virus infection | 20 | WP1438 | 2 | 0.5 | 1 | 1 | 1.28737203377495e-08 | 1.28737203377495e-08 |
| 19 | WP383 | Striated Muscle Contraction Pathway | 265 | WP383 | 38 | 0.61 | 0.565217391304348 | 0.652173913043478 | 1.03667354058147e-21 | 1.30607861950122e-08 |
| 20 | WP2542 | Sulindac Metabolic Pathway | 133 | WP2542 | 5 | 0.8 | 0.5 | 0.75 | 4.35964063989166e-11 | 2.5564111779557e-08 |
| 21 | WP4222 | Phosphodiesterases in neuronal function | 366 | WP4222 | 55 | 0.56 | 0.419354838709677 | 0.483870967741935 | 1.11151548949677e-22 | 3.51064709129753e-08 |
| 22 | WP2943 | Hypoxia-mediated EMT and Stemness | 191 | WP2943 | 2 | 1 | 0.5 | 0.5 | 1.87433487284931e-07 | 1.87433487284931e-07 |
| 23 | WP2874 | Liver X Receptor Pathway | 175 | WP2874 | 10 | 0.5 | 0.4 | 0.4 | 9.83107916736652e-08 | 2.35055233649832e-07 |
| 24 | WP466 | DNA Replication | 480 | WP466 | 42 | 0.98 | 0.634146341463415 | 0.75609756097561 | 3.91911842678923e-14 | 4.20885218710584e-07 |
| 25 | WP545 | Complement Activation | 528 | WP545 | 22 | 0.68 | 0.466666666666667 | 0.466666666666667 | 3.75341311013175e-54 | 6.35126956702113e-07 |
| 26 | WP4240 | Regulation of sister chromatid separation at the metaphase-anaphase transition | 374 | WP4240 | 16 | 0.94 | 0.533333333333333 | 0.533333333333333 | 4.41152154021936e-12 | 6.65380602412947e-07 |
| 27 | WP4300 | Extracellular vesicles in the crosstalk of cardiac cells | 395 | WP4300 | 28 | 0.61 | 0.411764705882353 | 0.588235294117647 | 1.55030261832076e-25 | 8.80494600850642e-07 |
| 28 | WP531 | DNA Mismatch Repair | 525 | WP531 | 22 | 0.95 | 0.523809523809524 | 0.571428571428571 | 3.57124737003596e-13 | 1.25145166671192e-06 |
| 29 | WP4589 | Major receptors targeted by epinephrine and norepinephrine | 471 | WP4589 | 15 | 0.73 | 0.636363636363636 | 0.636363636363636 | 1.11151548949677e-22 | 2.66815064645758e-06 |
| 30 | WP4760 | PKC-gamma calcium signaling pathway in ataxia | 508 | WP4760 | 22 | 0.55 | 0.416666666666667 | 0.583333333333333 | 6.52294438984146e-17 | 2.70719651941471e-06 |
| 31 | WP4191 | Caloric restriction and aging | 354 | WP4191 | 8 | 1 | 0.375 | 0.375 | 2.9447393377517e-11 | 3.80469322236512e-06 |
| 32 | WP2446 | Retinoblastoma Gene in Cancer | 117 | WP2446 | 88 | 0.98 | 0.546511627906977 | 0.593023255813954 | 1.96366351804733e-14 | 4.24785596200959e-06 |
| 33 | WP1992 | Genes targeted by miRNAs in adipocytes | 61 | WP1992 | 19 | 0.53 | 0.5 | 0.5 | 2.33586928012365e-14 | 8.49856030430427e-06 |
| 34 | WP4337 | ncRNAs involved in STAT3 signaling in hepatocellular carcinoma | 406 | WP4337 | 17 | 0.76 | 0.538461538461538 | 0.615384615384615 | 1.55030261832076e-25 | 9.36831691097847e-06 |
| 35 | WP2645 | Heroin metabolism | 145 | WP2645 | 3 | 0.67 | 0.5 | 1 | 1.87627142351219e-05 | 1.87627142351219e-05 |
| 36 | WP2826 | Cocaine metabolism | 158 | WP2826 | 4 | 0.5 | 0.5 | 1 | 1.87627142351219e-05 | 1.87627142351219e-05 |
| 37 | WP1602 | Nicotine Activity on Dopaminergic Neurons | 40 | WP1602 | 22 | 0.5 | 0.636363636363636 | 0.818181818181818 | 2.50026382158374e-16 | 2.24952453555091e-05 |
| 38 | WP4545 | Oxysterols derived from cholesterol | 452 | WP4545 | 18 | 0.56 | 0.6 | 0.6 | 1.46780086933461e-09 | 2.36116814219851e-05 |
| 39 | WP45 | G1 to S cell cycle control | 430 | WP45 | 64 | 0.95 | 0.491803278688525 | 0.573770491803279 | 3.91911842678923e-14 | 2.89588011644963e-05 |
| 40 | WP1495 | Glycine Metabolism | 24 | WP1495 | 4 | 0.75 | 0.666666666666667 | 0.666666666666667 | 7.32732034249336e-10 | 2.91348117795513e-05 |
| 41 | WP2879 | Farnesoid X Receptor Pathway | 180 | WP2879 | 19 | 0.37 | 0.428571428571429 | 0.428571428571429 | 1.03671457774015e-11 | 0.000129931976156264 |
| 42 | WP34 | Ovarian Infertility Genes | 211 | WP34 | 32 | 0.53 | 0.411764705882353 | 0.411764705882353 | 8.1728342950092e-20 | 0.000152471085336278 |
| 43 | WP516 | Hypertrophy Model | 519 | WP516 | 20 | 0.75 | 0.466666666666667 | 0.533333333333333 | 1.73723649603814e-29 | 0.000166791537749366 |
| 44 | WP247 | Small Ligand GPCRs | 121 | WP247 | 19 | 0.53 | 0.6 | 0.8 | 3.77273931182897e-18 | 0.000182717661150266 |
| 45 | WP2363 | Gastric Cancer Network 2 | 104 | WP2363 | 33 | 0.88 | 0.448275862068966 | 0.448275862068966 | 1.12863099668653e-15 | 0.000185246692246443 |
| 46 | WP170 | Nuclear Receptors | 44 | WP170 | 39 | 0.74 | 0.413793103448276 | 0.413793103448276 | 5.53853655041636e-45 | 0.000204208460415242 |
| 47 | WP3996 | Ethanol effects on histone modifications | 325 | WP3996 | 31 | 0.9 | 0.428571428571429 | 0.5 | 2.94021006969881e-38 | 0.000238758692258098 |
| 48 | WP4400 | FABP4 in ovarian cancer | 417 | WP4400 | 2 | 0.5 | 1 | 1 | 0.000245357066905715 | 0.000245357066905715 |
| 49 | WP58 | Monoamine GPCRs | 534 | WP58 | 33 | 0.15 | 0.6 | 0.6 | 2.66815064645758e-06 | 0.000266280491622695 |
| 50 | WP3679 | Cell-type Dependent Selectivity of CCK2R Signaling | 261 | WP3679 | 13 | 0.69 | 0.444444444444444 | 0.555555555555556 | 6.52294438984146e-17 | 0.000315427333264674 |
| 51 | WP2338 | miRNA Biogenesis | 99 | WP2338 | 8 | 0.75 | 0.5 | 0.5 | 5.52094234656009e-11 | 0.000633704399420972 |
| 52 | WP1455 | Serotonin Transporter Activity | 22 | WP1455 | 11 | 0.73 | 0.375 | 0.5 | 5.50097841431123e-07 | 0.000698192443745329 |
| 53 | WP4016 | DNA IR-damage and cellular response via ATR | 329 | WP4016 | 83 | 0.9 | 0.413333333333333 | 0.466666666666667 | 3.1984443894539e-16 | 0.000704575375419051 |
| 54 | WP179 | Cell Cycle | 48 | WP179 | 122 | 0.94 | 0.434782608695652 | 0.48695652173913 | 3.91911842678923e-14 | 0.000860192369254168 |
| 55 | WP2848 | Differentiation Pathway | 162 | WP2848 | 48 | 0.54 | 0.461538461538462 | 0.538461538461538 | 1.55030261832076e-25 | 0.000900218402911242 |
| 56 | WP2815 | Mammary gland development pathway - Involution (Stage 4 of 4) | 155 | WP2815 | 10 | 1 | 0.5 | 0.7 | 3.47598200773578e-10 | 0.000979886474579196 |
| 57 | WP322 | Osteoblast Signaling | 199 | WP322 | 14 | 0.5 | 0.428571428571429 | 0.428571428571429 | 1.60955895014834e-18 | 0.00122105800992755 |
| 58 | WP4583 | Biomarkers for urea cycle disorders | 467 | WP4583 | 12 | 0.67 | 0.375 | 0.375 | 1.05891161032475e-42 | 0.00125836568297114 |
| 59 | WP3893 | Development and heterogeneity of the ILC family | 289 | WP3893 | 32 | 0.56 | 0.5 | 0.555555555555556 | 1.55030261832076e-25 | 0.00137922281926359 |
| 60 | WP2406 | Cardiac Progenitor Differentiation | 112 | WP2406 | 53 | 0.57 | 0.466666666666667 | 0.5 | 5.00019440781505e-25 | 0.0019450999028179 |
| 61 | WP558 | Complement and Coagulation Cascades | 531 | WP558 | 59 | 0.66 | 0.41025641025641 | 0.487179487179487 | 3.75341311013175e-54 | 0.00204133415581446 |
| 62 | WP2516 | ATM Signaling Pathway | 127 | WP2516 | 40 | 0.92 | 0.405405405405405 | 0.459459459459459 | 6.96540853859659e-18 | 0.00226170199642674 |
| 63 | WP3876 | BMP2-WNT4-FOXO1 Pathway in Human Primary Endometrial Stromal Cell Differentiation | 282 | WP3876 | 13 | 0.85 | 0.454545454545455 | 0.454545454545455 | 1.1219536394885e-16 | 0.00287452439577986 |
| 64 | WP1545 | miRNAs involved in DNA damage response | 33 | WP1545 | 50 | 0.28 | 0.357142857142857 | 0.428571428571429 | 1.33825325438479e-13 | 0.00291300857028192 |
| 65 | WP3591 | Sleep regulation | 223 | WP3591 | 38 | 0.34 | 0.461538461538462 | 0.538461538461538 | 1.55030261832076e-25 | 0.00298637777295038 |
| 66 | WP2855 | Dopaminergic Neurogenesis | 166 | WP2855 | 30 | 0.33 | 0.4 | 0.6 | 8.1921343985721e-23 | 0.00300186445388684 |
| 67 | WP497 | Urea cycle and metabolism of amino groups | 515 | WP497 | 21 | 0.76 | 0.375 | 0.4375 | 1.21134935033961e-14 | 0.00350987947486594 |
| 68 | WP3407 | FTO Obesity Variant Mechanism | 212 | WP3407 | 8 | 0.88 | 0.428571428571429 | 0.428571428571429 | 2.9447393377517e-11 | 0.00376777148807062 |
| 69 | WP289 | Myometrial Relaxation and Contraction Pathways | 186 | WP289 | 158 | 0.76 | 0.391666666666667 | 0.466666666666667 | 4.72920713559152e-27 | 0.00465022180500277 |
| 70 | WP1530 | miRNA Regulation of DNA Damage Response | 27 | WP1530 | 93 | 0.69 | 0.375 | 0.453125 | 2.50026382158374e-16 | 0.00482551043459127 |
| 71 | WP4149 | White fat cell differentiation | 344 | WP4149 | 33 | 0.91 | 0.4 | 0.433333333333333 | 3.05550468161626e-32 | 0.00497520122591071 |
| 72 | WP2814 | Mammary gland development pathway - Puberty (Stage 2 of 4) | 154 | WP2814 | 13 | 0.92 | 0.5 | 0.5 | 8.1728342950092e-20 | 0.00569300599773054 |
| 73 | WP1603 | Nicotine Activity on Chromaffin Cells | 41 | WP1603 | 4 | 0.25 | 1 | 1 | 0.00581825930604642 | 0.00581825930604642 |
| 74 | WP4698 | Vitamin D-sensitive calcium signaling in depression | 486 | WP4698 | 41 | 0.54 | 0.363636363636364 | 0.5 | 6.52294438984146e-17 | 0.00581825930604642 |
| 75 | WP1971 | Integrated Cancer Pathway | 56 | WP1971 | 46 | 0.93 | 0.372093023255814 | 0.418604651162791 | 1.47590569356761e-12 | 0.00623426422936051 |
| 76 | WP4224 | Purine metabolism and related disorders | 368 | WP4224 | 22 | 0.86 | 0.368421052631579 | 0.421052631578947 | 3.39506009152496e-24 | 0.00660624701596271 |
| 77 | WP4259 | Disorders of Folate Metabolism and Transport | 379 | WP4259 | 13 | 0.85 | 0.454545454545455 | 0.454545454545455 | 7.32732034249336e-10 | 0.00660624701596271 |
| 78 | WP1601 | Fluoropyrimidine Activity | 39 | WP1601 | 34 | 0.82 | 0.392857142857143 | 0.5 | 7.38854762906026e-09 | 0.00668550277003425 |
| 79 | WP2806 | Human Complement System | 152 | WP2806 | 99 | 0.64 | 0.349206349206349 | 0.428571428571429 | 3.75341311013175e-54 | 0.00703640980157322 |
| 80 | WP707 | DNA Damage Response | 557 | WP707 | 69 | 0.9 | 0.370967741935484 | 0.451612903225806 | 2.50026382158374e-16 | 0.00934439177317729 |
| 81 | WP2895 | Differentiation of white and brown adipocyte | 187 | WP2895 | 25 | 0.72 | 0.388888888888889 | 0.388888888888889 | 4.791051754563e-15 | 0.00971361957709086 |
| 82 | WP1995 | Effects of Nitric Oxide | 62 | WP1995 | 8 | 0.5 | 0.5 | 0.75 | 3.39506009152496e-24 | 0.0112147264561884 |
| 83 | WP136 | Phase I biotransformations, non P450 | 10 | WP136 | 8 | 0.62 | 0.4 | 0.6 | 1.87627142351219e-05 | 0.0123569322150726 |
| 84 | WP536 | Calcium Regulation in the Cardiac Cell | 527 | WP536 | 152 | 0.7 | 0.355140186915888 | 0.429906542056075 | 7.92756655687513e-25 | 0.0169432049684982 |
| 85 | WP35 | G Protein Signaling Pathways | 216 | WP35 | 97 | 0.78 | 0.355263157894737 | 0.434210526315789 | 1.11151548949677e-22 | 0.0169866528793556 |
| 86 | WP241 | One Carbon Metabolism | 113 | WP241 | 31 | 0.81 | 0.4 | 0.48 | 7.32732034249336e-10 | 0.0170103318686093 |
| 87 | WP4571 | Urea cycle and related diseases | 464 | WP4571 | 9 | 0.67 | 0.5 | 0.5 | 6.0595781921859e-07 | 0.020635406510022 |
| 88 | WP4752 | Base Excision Repair | 503 | WP4752 | 31 | 0.97 | 0.4 | 0.466666666666667 | 3.57124737003596e-13 | 0.0220340720140378 |
| 89 | WP4720 | Eicosanoid metabolism via Cytochrome P450 Mono-Oxygenases (CYP) pathway | 491 | WP4720 | 9 | 0.44 | 0.5 | 0.5 | 4.43345799464762e-09 | 0.0230432320025256 |
| 90 | WP474 | Endochondral Ossification | 498 | WP474 | 65 | 0.83 | 0.351851851851852 | 0.462962962962963 | 4.81536487673321e-20 | 0.0246820506324245 |
| 91 | WP3875 | ATR Signaling | 281 | WP3875 | 9 | 0.89 | 0.375 | 0.375 | 4.60260415203756e-08 | 0.0248929712443472 |
| 92 | WP3959 | DNA IR-Double Strand Breaks (DSBs) and cellular response via ATM | 314 | WP3959 | 55 | 0.95 | 0.346153846153846 | 0.423076923076923 | 2.50026382158374e-16 | 0.0248929712443472 |
| 93 | WP4560 | MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement | 458 | WP4560 | 18 | 0.94 | 0.411764705882353 | 0.470588235294118 | 6.52294438984146e-17 | 0.0254612754912739 |
| 94 | WP2525 | Trans-sulfuration and one carbon metabolism | 128 | WP2525 | 32 | 0.88 | 0.357142857142857 | 0.464285714285714 | 7.32732034249336e-10 | 0.0321645449138761 |
| 95 | WP98 | Prostaglandin Synthesis and Regulation | 568 | WP98 | 45 | 0.82 | 0.378378378378378 | 0.459459459459459 | 2.17394413943821e-22 | 0.0332806226599994 |
| 96 | WP4304 | Oligodendrocyte Specification and differentiation(including remyelination), leading to Myelin Components for CNS | 397 | WP4304 | 31 | 0.52 | 0.375 | 0.375 | 7.83386153710323e-26 | 0.0344632354643189 |
| 97 | WP3599 | Transcription factor regulation in adipogenesis | 228 | WP3599 | 22 | 0.86 | 0.368421052631579 | 0.368421052631579 | 1.55030261832076e-25 | 0.0362388400314306 |
| 98 | WP1604 | Codeine and Morphine Metabolism | 42 | WP1604 | 15 | 0.27 | 0.5 | 0.5 | 6.49286728094462e-06 | 0.0372370714105519 |
| 99 | WP236 | Adipogenesis | 102 | WP236 | 131 | 0.79 | 0.346153846153846 | 0.413461538461538 | 3.75341311013175e-54 | 0.0373548404617312 |
| 100 | WP4661 | Amino Acid Metabolism Pathway Excerpt (Histidine catabolism extension) | 481 | WP4661 | 6 | 0.33 | 0.5 | 0.5 | 0.0431468886224066 | 0.0431468886224066 |
| 101 | WP3585 | Cytosine methylation | 222 | WP3585 | 9 | 0.89 | 0.375 | 0.5 | 7.49087453817701e-07 | 0.046146524101977 |
| 102 | WP3872 | Regulation of Apoptosis by Parathyroid Hormone-related Protein | 279 | WP3872 | 22 | 0.91 | 0.35 | 0.45 | 1.28737203377495e-08 | 0.0485074090657223 |
| 103 | WP4399 | MicroRNA network associated with chronic lymphocytic leukemia | 416 | WP4399 | 7 | 0.57 | 0.5 | 0.5 | 1.28737203377495e-08 | 0.0485074090657223 |
| 104 | WP53 | ID signaling pathway | 523 | WP53 | 16 | 0.81 | 0.307692307692308 | 0.384615384615385 | 1.33825325438479e-13 | 0.0542788662751285 |
| 105 | WP734 | Serotonin Receptor 4/6/7 and NR3C Signaling | 564 | WP734 | 19 | 0.84 | 0.3125 | 0.375 | 1.69191698398203e-15 | 0.0542788662751285 |
| 106 | WP2881 | Estrogen Receptor Pathway | 182 | WP2881 | 13 | 0.77 | 0.3 | 0.4 | 2.58938282317479e-38 | 0.0594386193019534 |
| 107 | WP3963 | Mevalonate pathway | 315 | WP3963 | 7 | 1 | 0.285714285714286 | 0.428571428571429 | 0.00314781622146767 | 0.0618737980244723 |
| 108 | WP2197 | Endothelin Pathways | 81 | WP2197 | 34 | 0.68 | 0.304347826086957 | 0.391304347826087 | 4.72920713559152e-27 | 0.0668243064530906 |
| 109 | WP2355 | Corticotropin-releasing hormone signaling pathway | 100 | WP2355 | 93 | 0.78 | 0.328767123287671 | 0.410958904109589 | 5.53853655041636e-45 | 0.0668243064530906 |
| 110 | WP727 | Monoamine Transport | 561 | WP727 | 32 | 0.53 | 0.294117647058824 | 0.529411764705882 | 4.62070637396041e-12 | 0.0730490654877152 |
| 111 | WP167 | Eicosanoid Synthesis | 43 | WP167 | 27 | 0.67 | 0.333333333333333 | 0.388888888888889 | 2.17394413943821e-22 | 0.0735098081465718 |
| 112 | WP3624 | Lung fibrosis | 235 | WP3624 | 63 | 0.67 | 0.30952380952381 | 0.428571428571429 | 1.55030261832076e-25 | 0.080115977530217 |
| 113 | WP4584 | Biomarkers for pyrimidine metabolism disorders | 468 | WP4584 | 15 | 0.8 | 0.333333333333333 | 0.5 | 2.56816439701713e-12 | 0.0832724893457054 |
| 114 | WP4204 | Tumor suppressor activity of SMARCB1 | 357 | WP4204 | 33 | 0.79 | 0.269230769230769 | 0.423076923076923 | 7.79200875278231e-09 | 0.0908144088489654 |
| 115 | WP4719 | Eicosanoid metabolism via Cyclo Oxygenases (COX) | 490 | WP4719 | 30 | 0.7 | 0.333333333333333 | 0.380952380952381 | 2.17394413943821e-22 | 0.0918721376616465 |
| 116 | WP3611 | Photodynamic therapy-induced AP-1 survival signaling. | 230 | WP3611 | 51 | 0.9 | 0.304347826086957 | 0.456521739130435 | 1.55030261832076e-25 | 0.093911573076689 |
| 117 | WP2011 | SREBF and miR33 in cholesterol and lipid homeostasis | 64 | WP2011 | 19 | 0.84 | 0.3125 | 0.4375 | 2.9447393377517e-11 | 0.103949453944605 |
| 118 | WP3892 | Development of pulmonary dendritic cells and macrophage subsets | 288 | WP3892 | 13 | 0.77 | 0.2 | 0.7 | 7.70437079680464e-06 | 0.111367348220358 |
| 119 | WP2431 | Spinal Cord Injury | 114 | WP2431 | 120 | 0.75 | 0.322222222222222 | 0.4 | 5.53853655041636e-45 | 0.114048118916392 |
| 120 | WP272 | Blood Clotting Cascade | 148 | WP272 | 23 | 0.52 | 0.333333333333333 | 0.5 | 1.05891161032475e-42 | 0.114803285411883 |
| 121 | WP117 | GPCRs, Other | 5 | WP117 | 94 | 0.23 | 0.318181818181818 | 0.363636363636364 | 3.77273931182897e-18 | 0.120172770046016 |
| 122 | WP3596 | miR-517 relationship with ARCN1 and USP1 | 227 | WP3596 | 5 | 1 | 0.2 | 0.4 | 7.70437079680464e-06 | 0.123137649892892 |
| 123 | WP3672 | LncRNA-mediated mechanisms of therapeutic resistance | 257 | WP3672 | 12 | 0.58 | 0.285714285714286 | 0.428571428571429 | 1.61117377276123e-06 | 0.123137649892892 |
| 124 | WP3995 | Prion disease pathway | 324 | WP3995 | 37 | 0.84 | 0.258064516129032 | 0.419354838709677 | 1.42295577093001e-17 | 0.148008766451471 |
| 125 | WP4147 | PTF1A related regulatory pathway | 342 | WP4147 | 11 | 0.45 | 0.2 | 0.4 | 0.000808563677475246 | 0.156029921726251 |
| 126 | WP2849 | Hematopoietic Stem Cell Differentiation | 163 | WP2849 | 63 | 0.68 | 0.325581395348837 | 0.395348837209302 | 1.4645909158934e-29 | 0.156167098725433 |
| 127 | WP3958 | GPR40 Pathway | 313 | WP3958 | 16 | 0.81 | 0.307692307692308 | 0.538461538461538 | 1.06179313771239e-06 | 0.156624702837221 |
| 128 | WP4249 | Hedgehog Signaling Pathway | 376 | WP4249 | 44 | 0.77 | 0.264705882352941 | 0.411764705882353 | 6.45939424963396e-09 | 0.171056939850016 |
| 129 | WP2846 | Proprotein convertase subtilisin/kexin type 9 (PCSK9) mediated LDL receptor degradation | 161 | WP2846 | 3 | 0.33 | 0 | 1 | 0.191601747736878 | 0.191601747736878 |
| 130 | WP3408 | Evolocumab Mechanism | 213 | WP3408 | 3 | 0.33 | 0 | 1 | 0.191601747736878 | 0.191601747736878 |
| 131 | WP2118 | Arrhythmogenic Right Ventricular Cardiomyopathy | 80 | WP2118 | 76 | 0.74 | 0.303571428571429 | 0.410714285714286 | 6.58880500842654e-23 | 0.19520059624092 |
| 132 | WP3640 | Imatinib and Chronic Myeloid Leukemia | 243 | WP3640 | 21 | 0.95 | 0.3 | 0.4 | 3.36912948711107e-08 | 0.202640916207215 |
| 133 | WP2007 | Iron metabolism in placenta | 63 | WP2007 | 12 | 0.67 | 0.25 | 0.375 | 0.000425327317103322 | 0.20667484530917 |
| 134 | WP129 | Matrix Metalloproteinases | 8 | WP129 | 30 | 0.73 | 0.272727272727273 | 0.409090909090909 | 1.66846236358396e-28 | 0.217106999492912 |
| 135 | WP4754 | IL-18 signaling pathway | 505 | WP4754 | 279 | 0.8 | 0.265765765765766 | 0.373873873873874 | 5.53853655041636e-45 | 0.224063872360977 |
| 136 | WP3301 | MFAP5-mediated ovarian cancer cell motility and invasiveness | 207 | WP3301 | 13 | 1 | 0.230769230769231 | 0.384615384615385 | 7.1834548445351e-10 | 0.236415904297976 |
| 137 | WP704 | Methylation Pathways | 555 | WP704 | 10 | 0.7 | 0.142857142857143 | 0.428571428571429 | 1.10795143781028e-12 | 0.241165469354808 |
| 138 | WP3930 | EDA Signalling in Hair Follicle Development | 297 | WP3930 | 14 | 0.64 | 0.222222222222222 | 0.555555555555556 | 6.78928901696758e-07 | 0.24293224118149 |
| 139 | WP3967 | miR-509-3p alteration of YAP1/ECM axis | 317 | WP3967 | 19 | 0.89 | 0.235294117647059 | 0.352941176470588 | 3.92971708713555e-06 | 0.246081089028509 |
| 140 | WP2858 | Ectoderm Differentiation | 168 | WP2858 | 144 | 0.78 | 0.285714285714286 | 0.366071428571429 | 6.10911950894992e-26 | 0.251410075884791 |
| 141 | WP428 | Wnt Signaling | 384 | WP428 | 118 | 0.79 | 0.301075268817204 | 0.365591397849462 | 5.00019440781505e-25 | 0.251410075884791 |
| 142 | WP1434 | Osteopontin Signaling | 19 | WP1434 | 13 | 1 | 0.230769230769231 | 0.461538461538462 | 1.51229007711679e-12 | 0.257536764433672 |
| 143 | WP176 | Folate Metabolism | 46 | WP176 | 73 | 0.6 | 0.295454545454545 | 0.409090909090909 | 1.55030261832076e-25 | 0.257536764433672 |
| 144 | WP28 | Selenium Metabolism and Selenoproteins | 150 | WP28 | 46 | 0.61 | 0.25 | 0.392857142857143 | 2.4987918295779e-23 | 0.257536764433672 |
| 145 | WP2840 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | 160 | WP2840 | 88 | 0.64 | 0.267857142857143 | 0.375 | 1.4645909158934e-29 | 0.257536764433672 |
| 146 | WP3617 | Photodynamic therapy-induced NF-kB survival signaling | 234 | WP3617 | 35 | 0.86 | 0.233333333333333 | 0.4 | 1.55030261832076e-25 | 0.257536764433672 |
| 147 | WP2059 | Alzheimers Disease | 75 | WP2059 | 150 | 0.46 | 0.260869565217391 | 0.36231884057971 | 6.52294438984146e-17 | 0.264407820025205 |
| 148 | WP4658 | Small cell lung cancer | 478 | WP4658 | 98 | 0.91 | 0.269662921348315 | 0.359550561797753 | 1.33825325438479e-13 | 0.266714097046007 |
| 149 | WP237 | Glucocorticoid and Mineralcorticoid Metabolism | 107 | WP237 | 8 | 0.25 | 0 | 0.5 | 0.273007477872406 | 0.273007477872406 |
| 150 | WP3287 | Overview of nanoparticle effects | 202 | WP3287 | 19 | 0.79 | 0.266666666666667 | 0.4 | 1.55030261832076e-25 | 0.292450502904674 |
| 151 | WP4586 | Metabolism of alpha-linolenic acid | 470 | WP4586 | 7 | 0.86 | 0.166666666666667 | 0.5 | 0.0386740237126384 | 0.296626199889639 |
| 152 | WP3580 | Methionine De Novo and Salvage Pathway | 220 | WP3580 | 22 | 0.86 | 0.210526315789474 | 0.368421052631579 | 4.35964063989166e-11 | 0.301026666733762 |
| 153 | WP4481 | Resistin as a regulator of inflammation | 422 | WP4481 | 33 | 0.85 | 0.25 | 0.357142857142857 | 1.55030261832076e-25 | 0.310639518319511 |
| 154 | WP3595 | mir-124 predicted interactions with cell cycle and differentiation | 226 | WP3595 | 7 | 0.86 | 0.333333333333333 | 0.5 | 1.28871879017951e-06 | 0.311537001183337 |
| 155 | WP4225 | Pyrimidine metabolism and related diseases | 369 | WP4225 | 17 | 0.71 | 0.25 | 0.416666666666667 | 1.65319775729734e-07 | 0.312696646387934 |
| 156 | WP24 | Peptide GPCRs | 111 | WP24 | 75 | 0.28 | 0.285714285714286 | 0.428571428571429 | 1.91116166189054e-21 | 0.317365436064072 |
| 157 | WP4336 | ncRNAs involved in Wnt signaling in hepatocellular carcinoma | 405 | WP4336 | 91 | 0.76 | 0.289855072463768 | 0.36231884057971 | 5.00019440781505e-25 | 0.320170838547363 |
| 158 | WP4462 | Platelet-mediated interactions with vascular and circulating cells | 418 | WP4462 | 17 | 0.88 | 0.266666666666667 | 0.4 | 1.28837373141904e-08 | 0.341095356415239 |
| 159 | WP4493 | Cells and Molecules involved in local acute inflammatory response | 426 | WP4493 | 17 | 0.76 | 0.307692307692308 | 0.384615384615385 | 1.55030261832076e-25 | 0.341095356415239 |
| 160 | WP3670 | Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway | 256 | WP3670 | 21 | 0.81 | 0.176470588235294 | 0.352941176470588 | 2.45932835171728e-12 | 0.357129134137342 |
| 161 | WP4538 | Regulatory circuits of the STAT3 signaling pathway | 447 | WP4538 | 79 | 0.85 | 0.26865671641791 | 0.343283582089552 | 1.91116166189054e-21 | 0.363878327573958 |
| 162 | WP229 | Irinotecan Pathway | 90 | WP229 | 13 | 0.54 | 0.285714285714286 | 0.428571428571429 | 1.87627142351219e-05 | 0.372595026103777 |
| 163 | WP4172 | PI3K-Akt Signaling Pathway | 350 | WP4172 | 345 | 0.73 | 0.281746031746032 | 0.361111111111111 | 1.96319556679318e-26 | 0.389653492019368 |
| 164 | WP3584 | MECP2 and Associated Rett Syndrome | 221 | WP3584 | 71 | 0.72 | 0.274509803921569 | 0.352941176470588 | 2.08918249834541e-15 | 0.389709140526829 |
| 165 | WP530 | Cytokines and Inflammatory Response | 524 | WP530 | 27 | 0.52 | 0.214285714285714 | 0.357142857142857 | 1.55030261832076e-25 | 0.394616722859002 |
| 166 | WP3888 | VEGFA-VEGFR2 Signaling Pathway | 286 | WP3888 | 438 | 0.92 | 0.255583126550869 | 0.359801488833747 | 5.53853655041636e-45 | 0.415827475604265 |
| 167 | WP4537 | Hippo-Yap signaling pathway | 446 | WP4537 | 23 | 1 | 0.130434782608696 | 0.347826086956522 | 1.54778757247964e-06 | 0.425582638865984 |
| 168 | WP4673 | Genes involved in male infertility | 483 | WP4673 | 155 | 0.55 | 0.223529411764706 | 0.352941176470588 | 8.15687289296435e-21 | 0.434708802034794 |
| 169 | WP4258 | LncRNA involvement in canonical Wnt signaling and colorectal cancer | 378 | WP4258 | 104 | 0.73 | 0.276315789473684 | 0.342105263157895 | 5.00019440781505e-25 | 0.442641490692933 |
| 170 | WP1528 | Physiological and Pathological Hypertrophy of the Heart | 26 | WP1528 | 25 | 0.96 | 0.291666666666667 | 0.375 | 1.45750470372243e-17 | 0.443468145964458 |
| 171 | WP1539 | Angiogenesis | 30 | WP1539 | 24 | 1 | 0.25 | 0.375 | 2.08918249834541e-15 | 0.443468145964458 |
| 172 | WP2586 | Aryl Hydrocarbon Receptor Netpath | 136 | WP2586 | 48 | 0.83 | 0.225 | 0.35 | 1.44400359316927e-08 | 0.452666162731714 |
| 173 | WP2865 | IL1 and megakaryocytes in obesity | 171 | WP2865 | 25 | 0.84 | 0.238095238095238 | 0.380952380952381 | 5.19525794232389e-10 | 0.452666162731714 |
| 174 | WP384 | Apoptosis Modulation by HSP70 | 266 | WP384 | 19 | 0.95 | 0.166666666666667 | 0.388888888888889 | 6.96540853859659e-18 | 0.452666162731714 |
| 175 | WP706 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | 556 | WP706 | 164 | 0.61 | 0.31 | 0.35 | 7.75341732836066e-26 | 0.452666162731714 |
| 176 | WP1742 | TP53 Network | 45 | WP1742 | 20 | 0.9 | 0.222222222222222 | 0.388888888888889 | 1.28737203377495e-08 | 0.467750156194828 |
| 177 | WP2507 | Nanomaterial induced apoptosis | 124 | WP2507 | 20 | 0.95 | 0.105263157894737 | 0.368421052631579 | 1.28737203377495e-08 | 0.467750156194828 |
| 178 | WP2267 | Synaptic Vesicle Pathway | 86 | WP2267 | 52 | 0.6 | 0.258064516129032 | 0.354838709677419 | 6.97840140254166e-30 | 0.492132771972666 |
| 179 | WP2038 | Regulation of Microtubule Cytoskeleton | 73 | WP2038 | 49 | 0.86 | 0.285714285714286 | 0.357142857142857 | 5.70447887867626e-23 | 0.498108980109511 |
| 180 | WP3594 | Circadian rhythm related genes | 225 | WP3594 | 207 | 0.67 | 0.289855072463768 | 0.340579710144928 | 1.86144948015588e-42 | 0.502912219194388 |
| 181 | WP186 | Homologous recombination | 51 | WP186 | 13 | 0.92 | 0.333333333333333 | 0.333333333333333 | 3.57124737003596e-13 | 0.503680038828547 |
| 182 | WP4299 | Lamin A-processing pathway | 392 | WP4299 | 3 | 1 | 0.333333333333333 | 0.333333333333333 | 0.0375633720082355 | 0.525565992204199 |
| 183 | WP26 | Signal Transduction of S1P Receptor | 139 | WP26 | 26 | 0.92 | 0.208333333333333 | 0.333333333333333 | 1.36035451223937e-09 | 0.537154575485495 |
| 184 | WP3932 | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway | 299 | WP3932 | 309 | 0.79 | 0.246913580246914 | 0.337448559670782 | 1.96319556679318e-26 | 0.55485006897197 |
| 185 | WP3529 | Zinc homeostasis | 218 | WP3529 | 37 | 0.65 | 0.208333333333333 | 0.333333333333333 | 1.09751947262418e-13 | 0.559735276252208 |
| 186 | WP3613 | Photodynamic therapy-induced unfolded protein response | 232 | WP3613 | 29 | 0.83 | 0.25 | 0.333333333333333 | 1.63572753987345e-09 | 0.592395677119481 |
| 187 | WP455 | GPCRs, Class A Rhodopsin-like | 454 | WP455 | 258 | 0.22 | 0.241379310344828 | 0.327586206896552 | 1.91116166189054e-21 | 0.594474156958518 |
| 188 | WP314 | Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation | 198 | WP314 | 44 | 0.91 | 0.175 | 0.325 | 1.28737203377495e-08 | 0.596740036001061 |
| 189 | WP4321 | Thermogenesis | 401 | WP4321 | 108 | 0.83 | 0.266666666666667 | 0.333333333333333 | 2.44977316588364e-24 | 0.602303776230422 |
| 190 | WP1533 | Vitamin B12 Metabolism | 29 | WP1533 | 53 | 0.57 | 0.2 | 0.333333333333333 | 1.55030261832076e-25 | 0.625924461178548 |
| 191 | WP254 | Apoptosis | 132 | WP254 | 86 | 0.93 | 0.225 | 0.3375 | 6.96540853859659e-18 | 0.630454225897172 |
| 192 | WP2817 | Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) | 157 | WP2817 | 33 | 0.76 | 0.32 | 0.32 | 8.1728342950092e-20 | 0.631033926043019 |
| 193 | WP4286 | Genotoxicity pathway | 386 | WP4286 | 63 | 0.78 | 0.244897959183673 | 0.326530612244898 | 6.52294438984146e-17 | 0.633739231633592 |
| 194 | WP4228 | Vitamin B6-dependent and responsive disorders | 370 | WP4228 | 5 | 0.8 | 0.25 | 0.25 | 0.00334024416831868 | 0.635216999029685 |
| 195 | WP306 | Focal Adhesion | 195 | WP306 | 202 | 0.86 | 0.248554913294798 | 0.323699421965318 | 1.96319556679318e-26 | 0.661870634611933 |
| 196 | WP3941 | Oxidative Damage | 306 | WP3941 | 41 | 0.9 | 0.243243243243243 | 0.324324324324324 | 1.28737203377495e-08 | 0.699923750757195 |
| 197 | WP561 | Heme Biosynthesis | 533 | WP561 | 9 | 0.89 | 0.25 | 0.25 | 6.5794345319789e-05 | 0.701076830955824 |
| 198 | WP4541 | Hippo-Merlin Signaling Dysregulation | 450 | WP4541 | 123 | 0.77 | 0.221052631578947 | 0.315789473684211 | 5.28168194977512e-22 | 0.723397294815617 |
| 199 | WP2064 | Neural Crest Differentiation | 77 | WP2064 | 102 | 0.63 | 0.25 | 0.328125 | 1.94200095136959e-19 | 0.727478052387628 |
| 200 | WP3678 | Amplification and Expansion of Oncogenic Pathways as Metastatic Traits | 260 | WP3678 | 17 | 1 | 0.117647058823529 | 0.294117647058824 | 6.04285700943382e-06 | 0.727478052387628 |
| 201 | WP3935 | Leptin Insulin Overlap | 302 | WP3935 | 17 | 0.82 | 0.285714285714286 | 0.285714285714286 | 9.45573250233619e-09 | 0.741018446305419 |
| 202 | WP1772 | Apoptosis Modulation and Signaling | 47 | WP1772 | 93 | 0.85 | 0.189873417721519 | 0.316455696202532 | 6.96540853859659e-18 | 0.744856843612274 |
| 203 | WP2877 | Vitamin D Receptor Pathway | 178 | WP2877 | 186 | 0.63 | 0.271186440677966 | 0.322033898305085 | 7.99040804992212e-20 | 0.818823949216948 |
| 204 | WP1591 | Heart Development | 37 | WP1591 | 46 | 0.65 | 0.266666666666667 | 0.3 | 1.16900918682e-14 | 0.842767793418932 |
| 205 | WP4357 | NRF2-ARE regulation | 410 | WP4357 | 23 | 0.96 | 0.227272727272727 | 0.318181818181818 | 6.33815645362995e-08 | 0.87065004588454 |
| 206 | WP2882 | Nuclear Receptors Meta-Pathway | 183 | WP2882 | 322 | 0.69 | 0.238738738738739 | 0.315315315315315 | 2.58938282317479e-38 | 0.88225486075262 |
| 207 | WP2032 | Human Thyroid Stimulating Hormone (TSH) signaling pathway | 68 | WP2032 | 68 | 0.91 | 0.274193548387097 | 0.32258064516129 | 8.47368187861688e-16 | 0.884931793800649 |
| 208 | WP3998 | Prader-Willi and Angelman Syndrome | 326 | WP3998 | 66 | 0.45 | 0.333333333333333 | 0.333333333333333 | 2.9765880724211e-12 | 0.892842095899067 |
| 209 | WP2369 | Histone Modifications | 106 | WP2369 | 70 | 0.43 | 0.166666666666667 | 0.3 | 4.29629046913145e-07 | 0.898693967045816 |
| 210 | WP4540 | Pathways Regulating Hippo Signaling | 449 | WP4540 | 99 | 0.81 | 0.225 | 0.325 | 1.45750470372243e-17 | 0.900720485325998 |
| 211 | WP4022 | Pyrimidine metabolism | 331 | WP4022 | 87 | 0.91 | 0.253164556962025 | 0.329113924050633 | 3.57124737003596e-13 | 0.90295173404126 |
| 212 | WP4484 | Control of immune tolerance by vasoactive intestinal peptide | 425 | WP4484 | 13 | 0.31 | 0 | 0.25 | 0.189083662421517 | 0.90837549057179 |
| 213 | WP3527 | Preimplantation Embryo | 217 | WP3527 | 60 | 0.52 | 0.193548387096774 | 0.290322580645161 | 1.4645909158934e-29 | 0.920619031124591 |
| 214 | WP408 | Oxidative Stress | 335 | WP408 | 34 | 0.85 | 0.206896551724138 | 0.310344827586207 | 2.4987918295779e-23 | 0.926181011736354 |
| 215 | WP4297 | Thiamine metabolic pathways | 390 | WP4297 | 9 | 0.89 | 0 | 0.25 | 0.171095325811961 | 0.927438681383965 |
| 216 | WP1984 | Integrated Breast Cancer Pathway | 59 | WP1984 | 155 | 0.92 | 0.27972027972028 | 0.314685314685315 | 3.61848623532521e-17 | 0.929014479457768 |
| 217 | WP3972 | PDGFR-beta pathway | 320 | WP3972 | 29 | 1 | 0.241379310344828 | 0.275862068965517 | 1.45750470372243e-17 | 0.936983896443534 |
| 218 | WP15 | Selenium Micronutrient Network | 25 | WP15 | 92 | 0.54 | 0.2 | 0.32 | 1.55030261832076e-25 | 0.94158668008034 |
| 219 | WP1423 | Ganglio Sphingolipid Metabolism | 14 | WP1423 | 13 | 0.62 | 0.25 | 0.25 | 4.87851969602103e-17 | 0.954898577153562 |
| 220 | WP4298 | Viral Acute Myocarditis | 391 | WP4298 | 85 | 0.82 | 0.228571428571429 | 0.314285714285714 | 1.55030261832076e-25 | 0.960973679911299 |
| 221 | WP2374 | Oncostatin M Signaling Pathway | 109 | WP2374 | 66 | 0.97 | 0.25 | 0.3125 | 1.45750470372243e-17 | 0.962619223865447 |
| 222 | WP3850 | Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling | 270 | WP3850 | 31 | 0.94 | 0.241379310344828 | 0.310344827586207 | 2.9447393377517e-11 | 0.979681670178472 |
| 223 | WP3657 | Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex | 250 | WP3657 | 22 | 0.86 | 0.315789473684211 | 0.315789473684211 | 1.28737203377495e-08 | 0.990973876560315 |
| 224 | WP465 | Tryptophan metabolism | 474 | WP465 | 42 | 0.64 | 0.259259259259259 | 0.333333333333333 | 1.2733947666864e-33 | 0.991085216247916 |
| 225 | WP1541 | Energy Metabolism | 31 | WP1541 | 48 | 0.88 | 0.30952380952381 | 0.333333333333333 | 4.7856489956754e-16 | 0.991457884585696 |
| 226 | WP4148 | Splicing factor NOVA regulated synaptic proteins | 343 | WP4148 | 42 | 0.74 | 0.258064516129032 | 0.32258064516129 | 8.59680057967434e-17 | 0.99308777325874 |
| 227 | WP2380 | Brain-Derived Neurotrophic Factor (BDNF) signaling pathway | 110 | WP2380 | 144 | 0.85 | 0.227642276422764 | 0.284552845528455 | 2.46076597989882e-17 | 0.993357395961217 |
| 228 | WP183 | Proteasome Degradation | 49 | WP183 | 64 | 0.91 | 0.189655172413793 | 0.258620689655172 | 0.000102727400071607 | 0.993739319892961 |
| 229 | WP3942 | PPAR signaling pathway | 307 | WP3942 | 67 | 0.67 | 0.244444444444444 | 0.266666666666667 | 4.45382103461115e-22 | 0.993946338790036 |
| 230 | WP4341 | Non-genomic actions of 1,25 dihydroxyvitamin D3 | 407 | WP4341 | 71 | 0.82 | 0.224137931034483 | 0.310344827586207 | 1.55030261832076e-25 | 0.997223465039722 |
| 231 | WP2036 | TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway | 71 | WP2036 | 42 | 0.95 | 0.2 | 0.3 | 1.55030261832076e-25 | 0.998306181536745 |
| 232 | WP262 | EBV LMP1 signaling | 140 | WP262 | 24 | 0.83 | 0.2 | 0.3 | 1.31802719833037e-09 | 0.998306181536745 |
| 233 | WP4008 | NO/cGMP/PKG mediated Neuroprotection | 328 | WP4008 | 48 | 0.52 | 0.24 | 0.32 | 3.3920313877351e-19 | 0.998306181536745 |
| 234 | WP4480 | Role of Altered Glycolysation of MUC1 in Tumour Microenvironment | 421 | WP4480 | 9 | 0.89 | 0.125 | 0.25 | 1.55030261832076e-25 | 0.998306181536745 |
| 235 | WP411 | mRNA Processing | 337 | WP411 | 133 | 0.92 | 0.204918032786885 | 0.286885245901639 | 7.40715848733595e-20 | 0.999556795185293 |
| 236 | WP4290 | Metabolic reprogramming in colon cancer | 388 | WP4290 | 44 | 0.89 | 0.230769230769231 | 0.282051282051282 | 1.21134935033961e-14 | 0.999559974562214 |
| 237 | WP2583 | T-Cell Receptor and Co-stimulatory Signaling | 135 | WP2583 | 29 | 0.93 | 0.0740740740740741 | 0.185185185185185 | 0.0020390189701393 | 0.999564052655054 |
| 238 | WP2113 | Type III interferon signaling | 79 | WP2113 | 10 | 0.6 | 0.333333333333333 | 0.333333333333333 | 0.000341914298724229 | 0.999577405939352 |
| 239 | WP2203 | Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway | 83 | WP2203 | 47 | 0.96 | 0.2 | 0.266666666666667 | 1.55030261832076e-25 | 0.999581638329153 |
| 240 | WP3929 | Chemokine signaling pathway | 296 | WP3929 | 165 | 0.75 | 0.233870967741935 | 0.306451612903226 | 1.11151548949677e-22 | 0.999581638329153 |
| 241 | WP2878 | PPAR Alpha Pathway | 179 | WP2878 | 26 | 0.62 | 0.3125 | 0.3125 | 2.35000378034819e-10 | 0.999593630002801 |
| 242 | WP4211 | Transcriptional cascade regulating adipogenesis | 361 | WP4211 | 13 | 1 | 0.307692307692308 | 0.307692307692308 | 3.05550468161626e-32 | 0.999597380647255 |
| 243 | WP395 | IL-4 Signaling Pathway | 312 | WP395 | 55 | 0.96 | 0.169811320754717 | 0.264150943396226 | 1.21006371795151e-15 | 0.999598637344068 |
| 244 | WP4756 | Renin Angiotensin Aldosterone System (RAAS) | 506 | WP4756 | 44 | 0.64 | 0.214285714285714 | 0.285714285714286 | 3.79036700534385e-25 | 0.999600844420397 |
| 245 | WP2037 | Prolactin Signaling Pathway | 72 | WP2037 | 76 | 0.96 | 0.164383561643836 | 0.246575342465753 | 1.21006371795151e-15 | 0.999622158178795 |
| 246 | WP3646 | Hepatitis C and Hepatocellular Carcinoma | 246 | WP3646 | 50 | 0.88 | 0.25 | 0.340909090909091 | 1.55030261832076e-25 | 0.999661972130556 |
| 247 | WP3414 | Initiation of transcription and translation elongation at the HIV-1 LTR | 215 | WP3414 | 37 | 0.73 | 0.259259259259259 | 0.296296296296296 | 1.30274002920557e-12 | 0.999679395222021 |
| 248 | WP1422 | Sphingolipid pathway | 13 | WP1422 | 30 | 0.8 | 0.166666666666667 | 0.25 | 3.69949076638916e-07 | 0.999680873684117 |
| 249 | WP4142 | Metabolism of Spingolipids in ER and Golgi apparatus | 340 | WP4142 | 20 | 0.75 | 0.2 | 0.2 | 1.78651764239784e-05 | 0.999680873684117 |
| 250 | WP4725 | Sphingolipid Metabolism (general overview) | 496 | WP4725 | 24 | 0.83 | 0.2 | 0.25 | 1.3073328528498e-06 | 0.999680873684117 |
| 251 | WP2359 | Parkin-Ubiquitin Proteasomal System pathway | 101 | WP2359 | 70 | 0.84 | 0.152542372881356 | 0.23728813559322 | 1.33825325438479e-13 | 0.999692096078023 |
| 252 | WP2911 | miRNA targets in ECM and membrane receptors | 188 | WP2911 | 43 | 0.51 | 0.227272727272727 | 0.272727272727273 | 1.96319556679318e-26 | 0.999694369321929 |
| 253 | WP4262 | Breast cancer pathway | 380 | WP4262 | 157 | 0.77 | 0.214876033057851 | 0.28099173553719 | 8.1728342950092e-20 | 0.999736194038243 |
| 254 | WP2636 | Common Pathways Underlying Drug Addiction | 141 | WP2636 | 42 | 0.57 | 0.166666666666667 | 0.25 | 8.80436312071741e-23 | 0.999745706039956 |
| 255 | WP2828 | Bladder Cancer | 159 | WP2828 | 41 | 0.93 | 0.184210526315789 | 0.289473684210526 | 2.88662493064661e-07 | 0.999745706039956 |
| 256 | WP3612 | Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling | 231 | WP3612 | 24 | 0.88 | 0.0952380952380952 | 0.238095238095238 | 1.21006371795151e-15 | 0.999752419955776 |
| 257 | WP4312 | Rett syndrome causing genes | 398 | WP4312 | 49 | 0.76 | 0.216216216216216 | 0.297297297297297 | 1.22943627951508e-14 | 0.999766525303437 |
| 258 | WP2533 | Glycerophospholipid Biosynthetic Pathway | 130 | WP2533 | 30 | 0.83 | 0.08 | 0.16 | 3.98592395806362e-10 | 0.999787685558907 |
| 259 | WP3940 | One carbon metabolism and related pathways | 305 | WP3940 | 54 | 0.72 | 0.230769230769231 | 0.256410256410256 | 2.86780567028817e-25 | 0.999787685558907 |
| 260 | WP4657 | 22q11.2 Deletion Syndrome | 477 | WP4657 | 92 | 0.63 | 0.258620689655172 | 0.310344827586207 | 5.10653311534479e-29 | 0.999801314777508 |
| 261 | WP382 | MAPK Signaling Pathway | 264 | WP382 | 249 | 0.78 | 0.261538461538462 | 0.302564102564103 | 5.53853655041636e-45 | 0.999829075430104 |
| 262 | WP4666 | Hepatitis B infection | 482 | WP4666 | 154 | 0.84 | 0.2 | 0.276923076923077 | 1.55030261832076e-25 | 0.999846173141814 |
| 263 | WP107 | Translation Factors | 3 | WP107 | 54 | 0.87 | 0.234042553191489 | 0.276595744680851 | 8.52450711689985e-13 | 0.999852323093054 |
| 264 | WP1424 | Globo Sphingolipid Metabolism | 15 | WP1424 | 21 | 0.95 | 0.2 | 0.2 | 4.87851969602103e-17 | 0.999852323093054 |
| 265 | WP1584 | Type II diabetes mellitus | 35 | WP1584 | 22 | 0.64 | 0.142857142857143 | 0.142857142857143 | 7.99040804992212e-20 | 0.999852323093054 |
| 266 | WP2018 | RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway | 65 | WP2018 | 55 | 0.95 | 0.0961538461538462 | 0.192307692307692 | 1.21006371795151e-15 | 0.999852323093054 |
| 267 | WP231 | TNF alpha Signaling Pathway | 94 | WP231 | 94 | 0.94 | 0.204545454545455 | 0.284090909090909 | 1.55030261832076e-25 | 0.999852323093054 |
| 268 | WP2371 | Parkinsons Disease Pathway | 108 | WP2371 | 84 | 0.37 | 0.193548387096774 | 0.290322580645161 | 6.96540853859659e-18 | 0.999852323093054 |
| 269 | WP244 | Alpha 6 Beta 4 signaling pathway | 116 | WP244 | 35 | 0.94 | 0.121212121212121 | 0.181818181818182 | 2.61142544133486e-11 | 0.999852323093054 |
| 270 | WP2453 | TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) | 119 | WP2453 | 16 | 0.94 | 0.0666666666666667 | 0.0666666666666667 | 1.10524321914212e-13 | 0.999852323093054 |
| 271 | WP2456 | HIF1A and PPARG regulation of glycolysis | 120 | WP2456 | 8 | 0.75 | 0.166666666666667 | 0.166666666666667 | 0.00320215171958638 | 0.999852323093054 |
| 272 | WP2854 | Gene regulatory network modelling somitogenesis | 165 | WP2854 | 11 | 0.55 | 0.166666666666667 | 0.166666666666667 | 0.0396104615656672 | 0.999852323093054 |
| 273 | WP2870 | Extracellular vesicle-mediated signaling in recipient cells | 173 | WP2870 | 30 | 0.9 | 0.185185185185185 | 0.222222222222222 | 1.47923810515956e-16 | 0.999852323093054 |
| 274 | WP3 | Phytochemical activity on NRF2 transcriptional activation | 193 | WP3 | 15 | 0.93 | 0.0714285714285714 | 0.214285714285714 | 0.00237947159212301 | 0.999852323093054 |
| 275 | WP3286 | Copper homeostasis | 201 | WP3286 | 54 | 0.87 | 0.234042553191489 | 0.297872340425532 | 3.71596808468601e-16 | 0.999852323093054 |
| 276 | WP3298 | Melatonin metabolism and effects | 204 | WP3298 | 42 | 0.62 | 0.269230769230769 | 0.307692307692308 | 1.86144948015588e-42 | 0.999852323093054 |
| 277 | WP3413 | NOTCH1 regulation of human endothelial cell calcification | 214 | WP3413 | 18 | 0.89 | 0.125 | 0.125 | 2.23804617426945e-12 | 0.999852323093054 |
| 278 | WP3601 | Composition of Lipid Particles | 229 | WP3601 | 10 | 0.4 | 0 | 0.25 | 0.191601747736878 | 0.999852323093054 |
| 279 | WP3633 | Caffeine and Theobromine metabolism | 239 | WP3633 | 4 | 0.25 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 280 | WP3664 | Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds | 253 | WP3664 | 18 | 0.89 | 0.1875 | 0.3125 | 8.33920870140507e-09 | 0.999852323093054 |
| 281 | WP3845 | Canonical and Non-canonical Notch signaling | 268 | WP3845 | 27 | 0.81 | 0.0909090909090909 | 0.181818181818182 | 0.000608063456248664 | 0.999852323093054 |
| 282 | WP3859 | TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition | 274 | WP3859 | 18 | 0.94 | 0.0588235294117647 | 0.0588235294117647 | 2.97846854097459e-06 | 0.999852323093054 |
| 283 | WP3931 | ESC Pluripotency Pathways | 298 | WP3931 | 119 | 0.7 | 0.265060240963855 | 0.289156626506024 | 1.04633266994318e-15 | 0.999852323093054 |
| 284 | WP3945 | TYROBP Causal Network | 310 | WP3945 | 63 | 0.9 | 0.12280701754386 | 0.175438596491228 | 1.51229007711679e-12 | 0.999852323093054 |
| 285 | WP3965 | Lipid Metabolism Pathway | 316 | WP3965 | 29 | 0.9 | 0.269230769230769 | 0.269230769230769 | 1.10524321914212e-13 | 0.999852323093054 |
| 286 | WP3982 | miRNA regulation of p53 pathway in prostate cancer | 322 | WP3982 | 34 | 0.68 | 0.0869565217391304 | 0.217391304347826 | 4.32292432502445e-07 | 0.999852323093054 |
| 287 | WP4153 | Degradation pathway of sphingolipids, including diseases | 346 | WP4153 | 10 | 0.8 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 288 | WP4156 | Biosynthesis and regeneration of tetrahydrobiopterin (BH4) and catabolism of phenylalanine, including diseases | 348 | WP4156 | 2 | 1 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 289 | WP4159 | GABA receptor Signaling | 349 | WP4159 | 33 | 0.39 | 0.0769230769230769 | 0.0769230769230769 | 0.0013300266749614 | 0.999852323093054 |
| 290 | WP4220 | Neurotransmitter Disorders | 365 | WP4220 | 4 | 0.25 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 291 | WP43 | Oxidation by Cytochrome P450 | 393 | WP43 | 63 | 0.48 | 0.133333333333333 | 0.166666666666667 | 7.53565262981462e-07 | 0.999852323093054 |
| 292 | WP4320 | The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome | 400 | WP4320 | 39 | 0.56 | 0.227272727272727 | 0.227272727272727 | 5.61788394294512e-16 | 0.999852323093054 |
| 293 | WP4342 | Vitamins A and D - action mechanisms | 408 | WP4342 | 3 | 1 | 0.333333333333333 | 0.333333333333333 | 1.20099662033474e-06 | 0.999852323093054 |
| 294 | WP437 | EGF/EGFR Signaling Pathway | 411 | WP437 | 164 | 0.95 | 0.206451612903226 | 0.232258064516129 | 1.4645909158934e-29 | 0.999852323093054 |
| 295 | WP4482 | Vitamin D in inflammatory diseases | 423 | WP4482 | 22 | 0.95 | 0.19047619047619 | 0.285714285714286 | 1.16949610776226e-27 | 0.999852323093054 |
| 296 | WP4483 | Relationship between inflammation, COX-2 and EGFR | 424 | WP4483 | 25 | 0.88 | 0.272727272727273 | 0.318181818181818 | 6.500496706318e-05 | 0.999852323093054 |
| 297 | WP4519 | Cerebral Organic Acidurias, including diseases | 435 | WP4519 | 7 | 1 | 0.285714285714286 | 0.285714285714286 | 1.97077141104003e-05 | 0.999852323093054 |
| 298 | WP4522 | Metabolic pathway of LDL, HDL and TG, including diseases | 437 | WP4522 | 17 | 0.53 | 0 | 0.222222222222222 | 0.0725218231021907 | 0.999852323093054 |
| 299 | WP4535 | Envelope proteins and their potential roles in EDMD physiopathology | 444 | WP4535 | 46 | 0.89 | 0.24390243902439 | 0.268292682926829 | 1.11151548949677e-22 | 0.999852323093054 |
| 300 | WP4549 | Fragile X Syndrome | 453 | WP4549 | 123 | 0.76 | 0.172043010752688 | 0.21505376344086 | 6.52294438984146e-17 | 0.999852323093054 |
| 301 | WP4562 | Canonical NF-KB pathway | 460 | WP4562 | 8 | 1 | 0 | 0.125 | 0.452666162731714 | 0.999852323093054 |
| 302 | WP4585 | Cancer immunotherapy by PD-1 blockade | 469 | WP4585 | 24 | 0.88 | 0.0952380952380952 | 0.19047619047619 | 2.79548473355309e-05 | 0.999852323093054 |
| 303 | WP4724 | Omega-9 FA synthesis | 495 | WP4724 | 16 | 0.75 | 0.166666666666667 | 0.25 | 9.83107916736652e-08 | 0.999852323093054 |
| 304 | WP4758 | Nephrotic syndrome | 507 | WP4758 | 45 | 0.73 | 0.151515151515152 | 0.181818181818182 | 7.19331431961561e-10 | 0.999852323093054 |
| 305 | WP550 | Biogenic Amine Synthesis | 529 | WP550 | 16 | 0.19 | 0.333333333333333 | 0.333333333333333 | 0.0013300266749614 | 0.999852323093054 |
| 306 | WP100 | Glutathione metabolism | 1 | WP100 | 23 | 0.7 | 0.0625 | 0.0625 | 2.4987918295779e-23 | 0.999852323093054 |
| 307 | WP106 | Alanine and aspartate metabolism | 2 | WP106 | 12 | 0.58 | 0.142857142857143 | 0.142857142857143 | 0.0013300266749614 | 0.999852323093054 |
| 308 | WP111 | Electron Transport Chain (OXPHOS system in mitochondria) | 4 | WP111 | 106 | 0.66 | 0.0714285714285714 | 0.128571428571429 | 1.43014316833318e-19 | 0.999852323093054 |
| 309 | WP12 | Osteoclast Signaling | 6 | WP12 | 16 | 0.75 | 0.166666666666667 | 0.25 | 1.51229007711679e-12 | 0.999852323093054 |
| 310 | WP134 | Pentose Phosphate Metabolism | 9 | WP134 | 7 | 1 | 0 | 0.142857142857143 | 0.154107526146787 | 0.999852323093054 |
| 311 | WP1403 | AMP-activated Protein Kinase (AMPK) Signaling | 12 | WP1403 | 69 | 0.81 | 0.178571428571429 | 0.25 | 7.99040804992212e-20 | 0.999852323093054 |
| 312 | WP143 | Fatty Acid Beta Oxidation | 17 | WP143 | 34 | 0.79 | 0.111111111111111 | 0.111111111111111 | 6.0888051023505e-05 | 0.999852323093054 |
| 313 | WP1433 | Nucleotide-binding Oligomerization Domain (NOD) pathway | 18 | WP1433 | 41 | 0.78 | 0.0625 | 0.125 | 4.08325260581342e-05 | 0.999852323093054 |
| 314 | WP1449 | Regulation of toll-like receptor signaling pathway | 21 | WP1449 | 145 | 0.77 | 0.117117117117117 | 0.198198198198198 | 1.55030261832076e-25 | 0.999852323093054 |
| 315 | WP1471 | Target Of Rapamycin (TOR) Signaling | 23 | WP1471 | 37 | 0.92 | 0.0882352941176471 | 0.117647058823529 | 8.28904921253337e-06 | 0.999852323093054 |
| 316 | WP1531 | Vitamin D Metabolism | 28 | WP1531 | 10 | 0.7 | 0.285714285714286 | 0.285714285714286 | 2.36116814219851e-05 | 0.999852323093054 |
| 317 | WP1544 | MicroRNAs in cardiomyocyte hypertrophy | 32 | WP1544 | 101 | 0.75 | 0.223684210526316 | 0.263157894736842 | 1.45750470372243e-17 | 0.999852323093054 |
| 318 | WP1589 | Folate-Alcohol and Cancer Pathway Hypotheses | 36 | WP1589 | 9 | 0.89 | 0.125 | 0.25 | 2.91348117795513e-05 | 0.999852323093054 |
| 319 | WP185 | Integrin-mediated Cell Adhesion | 50 | WP185 | 104 | 0.84 | 0.195402298850575 | 0.218390804597701 | 5.28168194977512e-22 | 0.999852323093054 |
| 320 | WP1941 | Peroxisomal beta-oxidation of tetracosanoyl-CoA | 52 | WP1941 | 4 | 1 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 321 | WP195 | IL-1 signaling pathway | 54 | WP195 | 57 | 0.96 | 0.127272727272727 | 0.181818181818182 | 1.5288509675647e-18 | 0.999852323093054 |
| 322 | WP197 | Cholesterol Biosynthesis Pathway | 55 | WP197 | 15 | 0.93 | 0.214285714285714 | 0.285714285714286 | 2.36116814219851e-05 | 0.999852323093054 |
| 323 | WP1982 | Sterol Regulatory Element-Binding Proteins (SREBP) signalling | 58 | WP1982 | 73 | 0.88 | 0.140625 | 0.171875 | 1.10524321914212e-13 | 0.999852323093054 |
| 324 | WP2035 | Follicle Stimulating Hormone (FSH) signaling pathway | 70 | WP2035 | 27 | 0.81 | 0.181818181818182 | 0.272727272727273 | 1.84528135455106e-08 | 0.999852323093054 |
| 325 | WP205 | IL-7 Signaling Pathway | 74 | WP205 | 25 | 1 | 0.16 | 0.2 | 0.000601597866207179 | 0.999852323093054 |
| 326 | WP2112 | IL17 signaling pathway | 78 | WP2112 | 32 | 0.84 | 0.148148148148148 | 0.222222222222222 | 1.31802719833037e-09 | 0.999852323093054 |
| 327 | WP22 | IL-9 Signaling Pathway | 82 | WP22 | 19 | 0.79 | 0.0666666666666667 | 0.0666666666666667 | 0.000601597866207179 | 0.999852323093054 |
| 328 | WP2249 | Metastatic brain tumor | 84 | WP2249 | 28 | 0.21 | 0.166666666666667 | 0.333333333333333 | 0.00291300857028192 | 0.999852323093054 |
| 329 | WP2261 | Signaling Pathways in Glioblastoma | 85 | WP2261 | 83 | 0.96 | 0.2375 | 0.25 | 1.45750470372243e-17 | 0.999852323093054 |
| 330 | WP2272 | Pathogenic Escherichia coli infection | 87 | WP2272 | 55 | 0.85 | 0.0851063829787234 | 0.191489361702128 | 4.18564642105688e-07 | 0.999852323093054 |
| 331 | WP2289 | Drug Induction of Bile Acid Pathway | 89 | WP2289 | 17 | 0.24 | 0.25 | 0.25 | 6.49286728094462e-06 | 0.999852323093054 |
| 332 | WP2291 | Deregulation of Rab and Rab Effector Genes in Bladder Cancer | 92 | WP2291 | 16 | 0.94 | 0.266666666666667 | 0.266666666666667 | 3.11005970071626e-15 | 0.999852323093054 |
| 333 | WP2324 | AGE/RAGE pathway | 95 | WP2324 | 66 | 0.95 | 0.142857142857143 | 0.206349206349206 | 1.45750470372243e-17 | 0.999852323093054 |
| 334 | WP2333 | Trans-sulfuration pathway | 98 | WP2333 | 10 | 1 | 0.2 | 0.2 | 7.49087453817701e-07 | 0.999852323093054 |
| 335 | WP2436 | Dopamine metabolism | 115 | WP2436 | 14 | 0.64 | 0.222222222222222 | 0.222222222222222 | 6.78665345557183e-11 | 0.999852323093054 |
| 336 | WP2447 | Amyotrophic lateral sclerosis (ALS) | 118 | WP2447 | 38 | 0.79 | 0.166666666666667 | 0.3 | 1.30274002920557e-12 | 0.999852323093054 |
| 337 | WP2485 | NAD Biosynthesis II (from tryptophan) | 122 | WP2485 | 8 | 0.75 | 0.166666666666667 | 0.166666666666667 | 1.2733947666864e-33 | 0.999852323093054 |
| 338 | WP2509 | Nanoparticle triggered autophagic cell death | 125 | WP2509 | 24 | 0.88 | 0.142857142857143 | 0.142857142857143 | 1.28737203377495e-08 | 0.999852323093054 |
| 339 | WP2513 | Nanoparticle triggered regulated necrosis | 126 | WP2513 | 12 | 0.92 | 0 | 0 | 0.795485118928105 | 0.999852323093054 |
| 340 | WP2526 | PDGF Pathway | 129 | WP2526 | 40 | 0.98 | 0.0769230769230769 | 0.128205128205128 | 1.21006371795151e-15 | 0.999852323093054 |
| 341 | WP2572 | Primary Focal Segmental Glomerulosclerosis FSGS | 134 | WP2572 | 74 | 0.78 | 0.275862068965517 | 0.310344827586207 | 4.81412003815079e-10 | 0.999852323093054 |
| 342 | WP2637 | Structural Pathway of Interleukin 1 (IL-1) | 142 | WP2637 | 50 | 0.98 | 0.142857142857143 | 0.204081632653061 | 1.21006371795151e-15 | 0.999852323093054 |
| 343 | WP2643 | Nanoparticle-mediated activation of receptor signaling | 144 | WP2643 | 29 | 0.97 | 0.178571428571429 | 0.214285714285714 | 0.00101315545629077 | 0.999852323093054 |
| 344 | WP268 | Notch Signaling | 147 | WP268 | 47 | 0.85 | 0.175 | 0.225 | 6.84417911248327e-08 | 0.999852323093054 |
| 345 | WP2805 | exRNA mechanism of action and biogenesis | 151 | WP2805 | 8 | 0.62 | 0.2 | 0.2 | 0.000217368536815086 | 0.999852323093054 |
| 346 | WP2813 | Mammary gland development pathway - Embryonic development (Stage 1 of 4) | 153 | WP2813 | 18 | 0.61 | 0.272727272727273 | 0.272727272727273 | 1.1219536394885e-16 | 0.999852323093054 |
| 347 | WP2853 | Endoderm Differentiation | 164 | WP2853 | 146 | 0.77 | 0.223214285714286 | 0.258928571428571 | 5.00019440781505e-25 | 0.999852323093054 |
| 348 | WP2857 | Mesodermal Commitment Pathway | 167 | WP2857 | 157 | 0.74 | 0.206896551724138 | 0.258620689655172 | 5.00019440781505e-25 | 0.999852323093054 |
| 349 | WP286 | IL-3 Signaling Pathway | 169 | WP286 | 49 | 0.9 | 0.159090909090909 | 0.204545454545455 | 1.21006371795151e-15 | 0.999852323093054 |
| 350 | WP2864 | Apoptosis-related network due to altered Notch3 in ovarian cancer | 170 | WP2864 | 54 | 0.93 | 0.16 | 0.28 | 4.12289297028431e-17 | 0.999852323093054 |
| 351 | WP2868 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | 172 | WP2868 | 5 | 1 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 352 | WP2873 | Aryl Hydrocarbon Receptor Pathway | 174 | WP2873 | 48 | 0.65 | 0.129032258064516 | 0.225806451612903 | 4.12289297028431e-17 | 0.999852323093054 |
| 353 | WP2875 | Constitutive Androstane Receptor Pathway | 176 | WP2875 | 32 | 0.53 | 0.176470588235294 | 0.235294117647059 | 2.9447393377517e-11 | 0.999852323093054 |
| 354 | WP2876 | Pregnane X Receptor pathway | 177 | WP2876 | 33 | 0.55 | 0.166666666666667 | 0.222222222222222 | 2.9447393377517e-11 | 0.999852323093054 |
| 355 | WP288 | NLR Proteins | 181 | WP288 | 9 | 0.89 | 0.125 | 0.125 | 0.00237947159212301 | 0.999852323093054 |
| 356 | WP2884 | NRF2 pathway | 184 | WP2884 | 146 | 0.66 | 0.1875 | 0.260416666666667 | 2.4987918295779e-23 | 0.999852323093054 |
| 357 | WP2889 | Oxytocin signaling | 185 | WP2889 | 4 | 0.5 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 358 | WP2916 | Interactome of polycomb repressive complex 2 (PRC2) | 189 | WP2916 | 17 | 0.94 | 0.1875 | 0.3125 | 6.05665966147348e-07 | 0.999852323093054 |
| 359 | WP2942 | DDX1 as a regulatory component of the Drosha microprocessor | 190 | WP2942 | 9 | 0.67 | 0 | 0 | 0.990973876560315 | 0.999852323093054 |
| 360 | WP299 | Nuclear Receptors in Lipid Metabolism and Toxicity | 192 | WP299 | 35 | 0.46 | 0.25 | 0.25 | 1.20099662033474e-06 | 0.999852323093054 |
| 361 | WP304 | Kit receptor signaling pathway | 194 | WP304 | 60 | 0.98 | 0.169491525423729 | 0.220338983050847 | 1.45750470372243e-17 | 0.999852323093054 |
| 362 | WP311 | Synthesis and Degradation of Ketone Bodies | 196 | WP311 | 5 | 1 | 0.2 | 0.2 | 6.0888051023505e-05 | 0.999852323093054 |
| 363 | WP313 | Signaling of Hepatocyte Growth Factor Receptor | 197 | WP313 | 34 | 1 | 0.176470588235294 | 0.205882352941176 | 1.21006371795151e-15 | 0.999852323093054 |
| 364 | WP325 | Triacylglyceride Synthesis | 200 | WP325 | 26 | 0.54 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 365 | WP3300 | Dual hijack model of Vif in HIV infection | 206 | WP3300 | 9 | 0.67 | 0 | 0.166666666666667 | 0.118228105072828 | 0.999852323093054 |
| 366 | WP3302 | eIF5A regulation in response to inhibition of the nuclear export system | 208 | WP3302 | 4 | 0.75 | 0.333333333333333 | 0.333333333333333 | 0.00071352422837791 | 0.999852323093054 |
| 367 | WP3303 | RAC1/PAK1/p38/MMP2 Pathway | 209 | WP3303 | 69 | 0.9 | 0.225806451612903 | 0.274193548387097 | 3.11796204582401e-18 | 0.999852323093054 |
| 368 | WP357 | Fatty Acid Biosynthesis | 219 | WP357 | 22 | 0.91 | 0.2 | 0.2 | 1.10524321914212e-13 | 0.999852323093054 |
| 369 | WP3593 | MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma | 224 | WP3593 | 9 | 0.78 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 370 | WP363 | Wnt Signaling Pathway (Netpath) | 237 | WP363 | 53 | 0.91 | 0.208333333333333 | 0.208333333333333 | 1.45750470372243e-17 | 0.999852323093054 |
| 371 | WP3630 | NAD metabolism, sirtuins and aging | 238 | WP3630 | 11 | 0.91 | 0.2 | 0.3 | 2.25748011539398e-08 | 0.999852323093054 |
| 372 | WP3634 | Insulin signalling in human adipocytes (normal condition) | 240 | WP3634 | 8 | 1 | 0.125 | 0.125 | 7.99040804992212e-20 | 0.999852323093054 |
| 373 | WP3635 | Insulin signalling in human adipocytes (diabetic condition) | 241 | WP3635 | 8 | 1 | 0.125 | 0.125 | 7.99040804992212e-20 | 0.999852323093054 |
| 374 | WP364 | IL-6 signaling pathway | 242 | WP364 | 43 | 0.95 | 0.24390243902439 | 0.24390243902439 | 1.55030261832076e-25 | 0.999852323093054 |
| 375 | WP3644 | NAD+ metabolism | 244 | WP3644 | 16 | 0.88 | 0.142857142857143 | 0.285714285714286 | 2.25748011539398e-08 | 0.999852323093054 |
| 376 | WP3645 | NAD+ biosynthetic pathways | 245 | WP3645 | 22 | 0.77 | 0.176470588235294 | 0.294117647058824 | 2.25748011539398e-08 | 0.999852323093054 |
| 377 | WP3651 | Pathways Affected in Adenoid Cystic Carcinoma | 247 | WP3651 | 66 | 0.85 | 0.196428571428571 | 0.25 | 2.89465973850597e-12 | 0.999852323093054 |
| 378 | WP3655 | Hypothetical Craniofacial Development Pathway | 248 | WP3655 | 8 | 0.75 | 0.166666666666667 | 0.166666666666667 | 0.00407427421601939 | 0.999852323093054 |
| 379 | WP3656 | Interleukin-1 Induced Activation of NF-kappa-B | 249 | WP3656 | 11 | 0.91 | 0.1 | 0.2 | 0.00279989180752429 | 0.999852323093054 |
| 380 | WP3658 | Wnt/beta-catenin Signaling Pathway in Leukemia | 251 | WP3658 | 26 | 0.81 | 0.333333333333333 | 0.333333333333333 | 1.28160819617811e-23 | 0.999852323093054 |
| 381 | WP366 | TGF-beta Signaling Pathway | 252 | WP366 | 133 | 0.96 | 0.2109375 | 0.234375 | 1.4645909158934e-29 | 0.999852323093054 |
| 382 | WP3668 | Hypothesized Pathways in Pathogenesis of Cardiovascular Disease | 255 | WP3668 | 25 | 0.92 | 0.217391304347826 | 0.304347826086957 | 1.91116166189054e-21 | 0.999852323093054 |
| 383 | WP3674 | Tgif disruption of Shh signaling | 258 | WP3674 | 9 | 0.44 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 384 | WP3676 | BDNF-TrkB Signaling | 259 | WP3676 | 34 | 0.88 | 0.166666666666667 | 0.2 | 1.84528135455106e-08 | 0.999852323093054 |
| 385 | WP368 | Mitochondrial LC-Fatty Acid Beta-Oxidation | 262 | WP368 | 17 | 0.94 | 0.0625 | 0.0625 | 0.0167383786864681 | 0.999852323093054 |
| 386 | WP3680 | Association Between Physico-Chemical Features and Toxicity Associated Pathways | 263 | WP3680 | 68 | 0.81 | 0.163636363636364 | 0.2 | 1.46702371634426e-15 | 0.999852323093054 |
| 387 | WP3844 | PI3K-AKT-mTOR signaling pathway and therapeutic opportunities | 267 | WP3844 | 30 | 1 | 0.2 | 0.2 | 6.62772818839576e-10 | 0.999852323093054 |
| 388 | WP3849 | MAPK and NFkB Signalling Pathways Inhibited by Yersinia YopJ | 269 | WP3849 | 12 | 1 | 0.166666666666667 | 0.25 | 1.31802719833037e-09 | 0.999852323093054 |
| 389 | WP3851 | TLR4 Signaling and Tolerance | 271 | WP3851 | 30 | 0.83 | 0.08 | 0.16 | 1.55030261832076e-25 | 0.999852323093054 |
| 390 | WP3853 | ERK Pathway in Huntington's Disease | 272 | WP3853 | 15 | 0.87 | 0.230769230769231 | 0.307692307692308 | 1.84528135455106e-08 | 0.999852323093054 |
| 391 | WP3858 | Toll-like Receptor Signaling related to MyD88 | 273 | WP3858 | 32 | 0.84 | 0 | 0.111111111111111 | 0.114048118916392 | 0.999852323093054 |
| 392 | WP3863 | T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection | 275 | WP3863 | 62 | 0.81 | 0.14 | 0.22 | 1.21006371795151e-15 | 0.999852323093054 |
| 393 | WP3865 | Novel intracellular components of RIG-I-like receptor (RLR) pathway | 276 | WP3865 | 61 | 0.84 | 0.137254901960784 | 0.235294117647059 | 3.37870774082303e-13 | 0.999852323093054 |
| 394 | WP3869 | Cannabinoid receptor signaling | 277 | WP3869 | 29 | 0.79 | 0.0869565217391304 | 0.130434782608696 | 3.92161302035637e-08 | 0.999852323093054 |
| 395 | WP3871 | Valproic acid pathway | 278 | WP3871 | 13 | 0.62 | 0.125 | 0.125 | 0.0102047891408715 | 0.999852323093054 |
| 396 | WP3874 | Canonical and Non-Canonical TGF-B signaling | 280 | WP3874 | 17 | 1 | 0.0588235294117647 | 0.235294117647059 | 1.47923810515956e-16 | 0.999852323093054 |
| 397 | WP3877 | Simplified Depiction of MYD88 Distinct Input-Output Pathway | 283 | WP3877 | 19 | 0.74 | 0 | 0.214285714285714 | 0.0594386193019534 | 0.999852323093054 |
| 398 | WP3878 | ATM Signaling Network in Development and Disease | 284 | WP3878 | 46 | 0.89 | 0.219512195121951 | 0.268292682926829 | 2.50026382158374e-16 | 0.999852323093054 |
| 399 | WP3879 | 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression | 285 | WP3879 | 18 | 1 | 0.111111111111111 | 0.111111111111111 | 2.45237666239285e-07 | 0.999852323093054 |
| 400 | WP391 | Mitochondrial Gene Expression | 290 | WP391 | 20 | 0.8 | 0.125 | 0.1875 | 2.9447393377517e-11 | 0.999852323093054 |
| 401 | WP3924 | Hfe effect on hepcidin production | 292 | WP3924 | 7 | 0.57 | 0.25 | 0.25 | 0.00378182889135815 | 0.999852323093054 |
| 402 | WP3925 | Amino Acid metabolism | 293 | WP3925 | 91 | 0.73 | 0.166666666666667 | 0.227272727272727 | 2.58938282317479e-38 | 0.999852323093054 |
| 403 | WP3927 | BMP Signaling Pathway in Eyelid Development | 295 | WP3927 | 20 | 0.8 | 0.1875 | 0.25 | 1.1219536394885e-16 | 0.999852323093054 |
| 404 | WP3933 | Kennedy pathway from Sphingolipids | 300 | WP3933 | 15 | 0.8 | 0.0833333333333333 | 0.0833333333333333 | 0.000153115641692463 | 0.999852323093054 |
| 405 | WP3934 | Leptin and adiponectin | 301 | WP3934 | 10 | 0.8 | 0.125 | 0.125 | 1.13349503425421e-06 | 0.999852323093054 |
| 406 | WP3937 | Microglia Pathogen Phagocytosis Pathway | 303 | WP3937 | 40 | 0.9 | 0.0833333333333333 | 0.0833333333333333 | 1.57756315705304e-09 | 0.999852323093054 |
| 407 | WP3938 | miR-222 in Exercise-Induced Cardiac Growth | 304 | WP3938 | 4 | 1 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 408 | WP3943 | Robo4 and VEGF Signaling Pathways Crosstalk | 308 | WP3943 | 6 | 1 | 0.333333333333333 | 0.333333333333333 | 1.76304737966141e-10 | 0.999852323093054 |
| 409 | WP3969 | H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity | 318 | WP3969 | 16 | 0.88 | 0.214285714285714 | 0.214285714285714 | 7.1806031181162e-15 | 0.999852323093054 |
| 410 | WP3971 | Role of Osx and miRNAs in tooth development | 319 | WP3971 | 36 | 0.28 | 0.2 | 0.2 | 1.74501293167954e-14 | 0.999852323093054 |
| 411 | WP3981 | miRNA regulation of prostate cancer signaling pathways | 321 | WP3981 | 59 | 0.54 | 0.15625 | 0.21875 | 1.28737203377495e-08 | 0.999852323093054 |
| 412 | WP399 | Wnt Signaling Pathway and Pluripotency | 323 | WP399 | 107 | 0.8 | 0.232558139534884 | 0.290697674418605 | 1.45750470372243e-17 | 0.999852323093054 |
| 413 | WP400 | p38 MAPK Signaling Pathway | 327 | WP400 | 34 | 0.97 | 0.181818181818182 | 0.242424242424242 | 4.7856489956754e-16 | 0.999852323093054 |
| 414 | WP4018 | Pathways in clear cell renal cell carcinoma | 330 | WP4018 | 87 | 0.91 | 0.164556962025316 | 0.189873417721519 | 1.10524321914212e-13 | 0.999852323093054 |
| 415 | WP405 | Eukaryotic Transcription Initiation | 334 | WP405 | 43 | 0.95 | 0.0975609756097561 | 0.146341463414634 | 2.41984712730741e-07 | 0.999852323093054 |
| 416 | WP410 | Exercise-induced Circadian Regulation | 336 | WP410 | 49 | 0.9 | 0.272727272727273 | 0.295454545454545 | 1.86144948015588e-42 | 0.999852323093054 |
| 417 | WP4136 | Fibrin Complement Receptor 3 Signaling Pathway | 338 | WP4136 | 42 | 0.71 | 0.0666666666666667 | 0.166666666666667 | 1.55030261832076e-25 | 0.999852323093054 |
| 418 | WP4141 | PI3K/AKT/mTOR - VitD3 Signalling | 339 | WP4141 | 22 | 0.86 | 0.263157894736842 | 0.263157894736842 | 3.87043570690072e-12 | 0.999852323093054 |
| 419 | WP4146 | Macrophage markers | 341 | WP4146 | 9 | 1 | 0 | 0.111111111111111 | 0.21102640351702 | 0.999852323093054 |
| 420 | WP4150 | Wnt Signaling in Kidney Disease | 345 | WP4150 | 39 | 0.69 | 0.222222222222222 | 0.222222222222222 | 8.33920870140507e-09 | 0.999852323093054 |
| 421 | WP4155 | Endometrial cancer | 347 | WP4155 | 63 | 0.94 | 0.152542372881356 | 0.220338983050847 | 1.04633266994318e-15 | 0.999852323093054 |
| 422 | WP4186 | Somatroph axis (GH) and its relationship to dietary restriction and aging | 352 | WP4186 | 6 | 1 | 0.333333333333333 | 0.333333333333333 | 2.25748011539398e-08 | 0.999852323093054 |
| 423 | WP4189 | Mevalonate arm of cholesterol biosynthesis pathway with inhibitors | 353 | WP4189 | 2 | 1 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 424 | WP4197 | The human immune response to tuberculosis | 356 | WP4197 | 23 | 1 | 0.130434782608696 | 0.130434782608696 | 0.000341914298724229 | 0.999852323093054 |
| 425 | WP4205 | MET in type 1 papillary renal cell carcinoma | 358 | WP4205 | 59 | 0.88 | 0.115384615384615 | 0.173076923076923 | 3.90142119029615e-06 | 0.999852323093054 |
| 426 | WP4206 | Hereditary leiomyomatosis and renal cell carcinoma pathway | 359 | WP4206 | 20 | 0.95 | 0.105263157894737 | 0.210526315789474 | 2.03101031117154e-10 | 0.999852323093054 |
| 427 | WP4210 | Tryptophan catabolism leading to NAD+ production | 360 | WP4210 | 16 | 0.69 | 0.0909090909090909 | 0.0909090909090909 | 1.2733947666864e-33 | 0.999852323093054 |
| 428 | WP4217 | Ebola Virus Pathway on Host | 363 | WP4217 | 132 | 0.89 | 0.135593220338983 | 0.186440677966102 | 7.15702783093164e-17 | 0.999852323093054 |
| 429 | WP422 | MAPK Cascade | 364 | WP422 | 33 | 1 | 0.212121212121212 | 0.272727272727273 | 1.06179313771239e-06 | 0.999852323093054 |
| 430 | WP4223 | Ras Signaling | 367 | WP4223 | 186 | 0.76 | 0.204225352112676 | 0.26056338028169 | 2.6982385516733e-21 | 0.999852323093054 |
| 431 | WP4236 | Disorders of the Krebs cycle | 372 | WP4236 | 7 | 1 | 0.142857142857143 | 0.142857142857143 | 0.000542153786249434 | 0.999852323093054 |
| 432 | WP4239 | Epithelial to mesenchymal transition in colorectal cancer | 373 | WP4239 | 164 | 0.78 | 0.1953125 | 0.2578125 | 5.10653311534479e-29 | 0.999852323093054 |
| 433 | WP4241 | Type 2 papillary renal cell carcinoma | 375 | WP4241 | 36 | 0.83 | 0.133333333333333 | 0.166666666666667 | 6.62772818839576e-10 | 0.999852323093054 |
| 434 | WP4255 | Non-small cell lung cancer | 377 | WP4255 | 72 | 0.93 | 0.149253731343284 | 0.238805970149254 | 1.45750470372243e-17 | 0.999852323093054 |
| 435 | WP4263 | Pancreatic adenocarcinoma pathway | 381 | WP4263 | 89 | 0.96 | 0.141176470588235 | 0.211764705882353 | 1.47923810515956e-16 | 0.999852323093054 |
| 436 | WP4271 | Vitamin B12 Disorders | 383 | WP4271 | 13 | 0.69 | 0 | 0.222222222222222 | 0.105553301023444 | 0.999852323093054 |
| 437 | WP4292 | Methionine metabolism leading to Sulphur Amino Acids and related disorders | 389 | WP4292 | 11 | 0.82 | 0.222222222222222 | 0.222222222222222 | 5.6500805039415e-14 | 0.999852323093054 |
| 438 | WP430 | Statin Pathway | 394 | WP430 | 33 | 0.45 | 0.133333333333333 | 0.266666666666667 | 0.00133659811986492 | 0.999852323093054 |
| 439 | WP4313 | Ferroptosis | 399 | WP4313 | 40 | 0.9 | 0.138888888888889 | 0.194444444444444 | 1.14291084616521e-05 | 0.999852323093054 |
| 440 | WP4331 | Neovascularisation processes | 404 | WP4331 | 37 | 1 | 0.189189189189189 | 0.27027027027027 | 3.37870774082303e-13 | 0.999852323093054 |
| 441 | WP4352 | Ciliary landscape | 409 | WP4352 | 220 | 0.9 | 0.137055837563452 | 0.208121827411168 | 4.19419091059679e-15 | 0.999852323093054 |
| 442 | WP4389 | Bile Acids synthesis and enterohepatic circulation | 413 | WP4389 | 13 | 0.38 | 0 | 0.2 | 0.191601747736878 | 0.999852323093054 |
| 443 | WP4396 | Nonalcoholic fatty liver disease | 414 | WP4396 | 160 | 0.84 | 0.133333333333333 | 0.207407407407407 | 1.55030261832076e-25 | 0.999852323093054 |
| 444 | WP4397 | Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors | 415 | WP4397 | 3 | 0.67 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 445 | WP4478 | LTF danger signal response pathway | 419 | WP4478 | 20 | 0.7 | 0.0714285714285714 | 0.214285714285714 | 1.55030261832076e-25 | 0.999852323093054 |
| 446 | WP4479 | Supression of HMGB1 mediated inflammation by THBD | 420 | WP4479 | 9 | 1 | 0 | 0.111111111111111 | 0.452666162731714 | 0.999852323093054 |
| 447 | WP4494 | Selective expression of chemokine receptors during T-cell polarization | 427 | WP4494 | 29 | 0.55 | 0.0625 | 0.125 | 0.00407427421601939 | 0.999852323093054 |
| 448 | WP4496 | Signal transduction through IL1R | 429 | WP4496 | 35 | 0.86 | 0.133333333333333 | 0.233333333333333 | 1.55030261832076e-25 | 0.999852323093054 |
| 449 | WP4504 | Cysteine and methionine catabolism | 431 | WP4504 | 15 | 0.87 | 0.153846153846154 | 0.153846153846154 | 5.6500805039415e-14 | 0.999852323093054 |
| 450 | WP4506 | Tyrosine Metabolism | 432 | WP4506 | 4 | 0.25 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 451 | WP4518 | Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases | 434 | WP4518 | 10 | 0.5 | 0.2 | 0.2 | 0.000377573164229441 | 0.999852323093054 |
| 452 | WP4521 | Glycosylation and related congenital defects | 436 | WP4521 | 25 | 1 | 0.12 | 0.16 | 1.02496252421453e-08 | 0.999852323093054 |
| 453 | WP4523 | Classical pathway of steroidogenesis, including diseases | 438 | WP4523 | 16 | 0.31 | 0 | 0.2 | 0.273007477872406 | 0.999852323093054 |
| 454 | WP4524 | The alternative pathway of fetal androgen synthesis | 439 | WP4524 | 12 | 0.33 | 0.25 | 0.25 | 2.8033361067803e-09 | 0.999852323093054 |
| 455 | WP453 | Inflammatory Response Pathway | 440 | WP453 | 33 | 0.67 | 0.0909090909090909 | 0.181818181818182 | 0.000442098767154395 | 0.999852323093054 |
| 456 | WP4532 | Intraflagellar transport proteins binding to dynein | 441 | WP4532 | 27 | 0.93 | 0.08 | 0.16 | 0.00558066527342552 | 0.999852323093054 |
| 457 | WP4533 | Transcription co-factors SKI and SKIL protein partners | 442 | WP4533 | 18 | 1 | 0.166666666666667 | 0.277777777777778 | 1.54778757247964e-06 | 0.999852323093054 |
| 458 | WP4536 | Genes related to primary cilium development (based on CRISPR) | 445 | WP4536 | 103 | 0.92 | 0.105263157894737 | 0.189473684210526 | 8.57900007846234e-13 | 0.999852323093054 |
| 459 | WP4539 | Synaptic signaling pathways associated with autism spectrum disorder | 448 | WP4539 | 51 | 0.76 | 0.256410256410256 | 0.256410256410256 | 9.26038985479124e-09 | 0.999852323093054 |
| 460 | WP4542 | Overview of leukocyte-intrinsic Hippo pathway functions | 451 | WP4542 | 36 | 0.86 | 0.161290322580645 | 0.258064516129032 | 1.54778757247964e-06 | 0.999852323093054 |
| 461 | WP4553 | FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma | 455 | WP4553 | 38 | 0.29 | 0.181818181818182 | 0.272727272727273 | 3.04356671038824e-07 | 0.999852323093054 |
| 462 | WP4559 | Interactions between immune cells and microRNAs in tumor microenvironment | 457 | WP4559 | 40 | 0.6 | 0.125 | 0.25 | 1.47923810515956e-16 | 0.999852323093054 |
| 463 | WP4561 | Cell migration and invasion through p75NTR | 459 | WP4561 | 31 | 0.9 | 0.214285714285714 | 0.285714285714286 | 3.88351886854851e-13 | 0.999852323093054 |
| 464 | WP4564 | Neural Crest Cell Migration during Development | 461 | WP4564 | 41 | 0.8 | 0.151515151515152 | 0.242424242424242 | 1.21006371795151e-15 | 0.999852323093054 |
| 465 | WP4565 | Neural Crest Cell Migration in Cancer | 462 | WP4565 | 44 | 0.82 | 0.166666666666667 | 0.25 | 1.21006371795151e-15 | 0.999852323093054 |
| 466 | WP4577 | Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway | 465 | WP4577 | 44 | 0.98 | 0.0930232558139535 | 0.116279069767442 | 0.000303680199088757 | 0.999852323093054 |
| 467 | WP4595 | Urea cycle and associated pathways | 472 | WP4595 | 21 | 0.76 | 0.25 | 0.3125 | 1.21134935033961e-14 | 0.999852323093054 |
| 468 | WP4629 | Computational Model of Aerobic Glycolysis | 473 | WP4629 | 12 | 0.92 | 0.181818181818182 | 0.181818181818182 | 1.94971495989183e-05 | 0.999852323093054 |
| 469 | WP4655 | Cytosolic DNA-sensing pathway | 475 | WP4655 | 76 | 0.72 | 0.109090909090909 | 0.145454545454545 | 1.55030261832076e-25 | 0.999852323093054 |
| 470 | WP4659 | Gastrin Signaling Pathway | 479 | WP4659 | 114 | 0.92 | 0.180952380952381 | 0.238095238095238 | 4.7856489956754e-16 | 0.999852323093054 |
| 471 | WP4674 | Head and Neck Squamous Cell Carcinoma | 484 | WP4674 | 70 | 0.94 | 0.121212121212121 | 0.166666666666667 | 1.47923810515956e-16 | 0.999852323093054 |
| 472 | WP4685 | Melanoma | 485 | WP4685 | 68 | 0.93 | 0.174603174603175 | 0.26984126984127 | 1.21006371795151e-15 | 0.999852323093054 |
| 473 | WP47 | Hedgehog Signaling Pathway Netpath | 487 | WP47 | 16 | 0.75 | 0.0833333333333333 | 0.25 | 0.0317273821116764 | 0.999852323093054 |
| 474 | WP4705 | Pathways of nucleic acid metabolism and innate immune sensing | 488 | WP4705 | 16 | 0.81 | 0.153846153846154 | 0.153846153846154 | 1.16208386478435e-12 | 0.999852323093054 |
| 475 | WP4718 | Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) | 489 | WP4718 | 47 | 0.87 | 0.219512195121951 | 0.268292682926829 | 1.16398114740138e-08 | 0.999852323093054 |
| 476 | WP4721 | Eicosanoid metabolism via Lipo Oxygenases (LOX) | 492 | WP4721 | 29 | 0.69 | 0.2 | 0.25 | 4.45382103461115e-22 | 0.999852323093054 |
| 477 | WP4722 | Glycerolipids and Glycerophospholipids | 493 | WP4722 | 24 | 0.75 | 0.0555555555555556 | 0.0555555555555556 | 0.000153115641692463 | 0.999852323093054 |
| 478 | WP4723 | Omega-3/Omega-6 FA synthesis | 494 | WP4723 | 15 | 0.73 | 0 | 0.0909090909090909 | 0.296626199889639 | 0.999852323093054 |
| 479 | WP4726 | Sphingolipid Metabolism (integrated pathway) | 497 | WP4726 | 25 | 0.84 | 0.19047619047619 | 0.238095238095238 | 1.3073328528498e-06 | 0.999852323093054 |
| 480 | WP4742 | Ketogenesis and Ketolysis | 499 | WP4742 | 8 | 1 | 0.125 | 0.125 | 6.0888051023505e-05 | 0.999852323093054 |
| 481 | WP4746 | Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism | 500 | WP4746 | 95 | 0.69 | 0.227272727272727 | 0.272727272727273 | 2.44977316588364e-24 | 0.999852323093054 |
| 482 | WP4747 | Netrin-UNC5B signaling Pathway | 501 | WP4747 | 52 | 0.85 | 0.181818181818182 | 0.272727272727273 | 2.5665992363522e-08 | 0.999852323093054 |
| 483 | WP4751 | HIPK2 in kidney fibrosis | 502 | WP4751 | 2 | 1 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 484 | WP4753 | Nucleotide Excision Repair | 504 | WP4753 | 44 | 0.98 | 0.255813953488372 | 0.27906976744186 | 3.57124737003596e-13 | 0.999852323093054 |
| 485 | WP4767 | FGFR3 signalling in chondrocyte proliferation and terminal differentiation | 509 | WP4767 | 27 | 0.89 | 0.166666666666667 | 0.25 | 1.60955895014834e-18 | 0.999852323093054 |
| 486 | WP477 | Cytoplasmic Ribosomal Proteins | 510 | WP477 | 91 | 0.93 | 0.129411764705882 | 0.164705882352941 | 8.56966962716958e-10 | 0.999852323093054 |
| 487 | WP4792 | Purine metabolism | 511 | WP4792 | 13 | 0.85 | 0.272727272727273 | 0.272727272727273 | 3.92279863878209e-05 | 0.999852323093054 |
| 488 | WP481 | Insulin Signaling | 512 | WP481 | 161 | 0.93 | 0.186666666666667 | 0.246666666666667 | 2.30627807010563e-26 | 0.999852323093054 |
| 489 | WP49 | IL-2 Signaling Pathway | 513 | WP49 | 42 | 0.98 | 0.195121951219512 | 0.24390243902439 | 1.21006371795151e-15 | 0.999852323093054 |
| 490 | WP496 | Steroid Biosynthesis | 514 | WP496 | 10 | 0.4 | 0 | 0.25 | 0.386085732506969 | 0.999852323093054 |
| 491 | WP500 | Glycogen Synthesis and Degradation | 516 | WP500 | 40 | 0.9 | 0.138888888888889 | 0.194444444444444 | 9.51262628208688e-25 | 0.999852323093054 |
| 492 | WP51 | Regulation of Actin Cytoskeleton | 518 | WP51 | 151 | 0.77 | 0.213675213675214 | 0.273504273504274 | 1.04633266994318e-15 | 0.999852323093054 |
| 493 | WP521 | Amino acid conjugation of benzoic acid | 520 | WP521 | 5 | 0.2 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 494 | WP524 | G13 Signaling Pathway | 521 | WP524 | 41 | 0.85 | 0.2 | 0.2 | 6.63243812483213e-11 | 0.999852323093054 |
| 495 | WP528 | Acetylcholine Synthesis | 522 | WP528 | 7 | 0.57 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 496 | WP534 | Glycolysis and Gluconeogenesis | 526 | WP534 | 45 | 0.73 | 0.121212121212121 | 0.121212121212121 | 7.99040804992212e-20 | 0.999852323093054 |
| 497 | WP560 | TGF-beta Receptor Signaling | 532 | WP560 | 58 | 0.79 | 0.217391304347826 | 0.260869565217391 | 1.47923810515956e-16 | 0.999852323093054 |
| 498 | WP581 | EPO Receptor Signaling | 535 | WP581 | 26 | 0.96 | 0.08 | 0.08 | 0.000601597866207179 | 0.999852323093054 |
| 499 | WP585 | Interferon type I signaling pathways | 536 | WP585 | 55 | 0.95 | 0.173076923076923 | 0.230769230769231 | 9.45573250233619e-09 | 0.999852323093054 |
| 500 | WP61 | Notch Signaling Pathway Netpath | 537 | WP61 | 63 | 0.9 | 0.157894736842105 | 0.280701754385965 | 4.8712821556021e-23 | 0.999852323093054 |
| 501 | WP615 | Senescence and Autophagy in Cancer | 538 | WP615 | 108 | 0.86 | 0.193548387096774 | 0.258064516129032 | 1.55030261832076e-25 | 0.999852323093054 |
| 502 | WP623 | Oxidative phosphorylation | 540 | WP623 | 62 | 0.6 | 0 | 0.0540540540540541 | 0.0626324188453113 | 0.999852323093054 |
| 503 | WP673 | ErbB Signaling Pathway | 542 | WP673 | 91 | 0.89 | 0.209876543209877 | 0.259259259259259 | 3.46021469111041e-20 | 0.999852323093054 |
| 504 | WP678 | Arachidonate Epoxygenase / Epoxide Hydrolase | 543 | WP678 | 7 | 0.71 | 0.2 | 0.2 | 4.43345799464762e-09 | 0.999852323093054 |
| 505 | WP688 | Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) | 544 | WP688 | 5 | 0.6 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 506 | WP690 | Polyol Pathway | 546 | WP690 | 4 | 0.75 | 0 | 0 | 0.855645046418417 | 0.999852323093054 |
| 507 | WP692 | Sulfation Biotransformation Reaction | 548 | WP692 | 19 | 0.32 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 508 | WP694 | Arylamine metabolism | 549 | WP694 | 6 | 0.33 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 509 | WP696 | Benzo(a)pyrene metabolism | 550 | WP696 | 9 | 0.78 | 0 | 0.142857142857143 | 0.186101834726753 | 0.999852323093054 |
| 510 | WP697 | Estrogen metabolism | 551 | WP697 | 19 | 0.47 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 511 | WP698 | Glucuronidation | 552 | WP698 | 26 | 0.35 | 0.222222222222222 | 0.222222222222222 | 2.6913627863713e-23 | 0.999852323093054 |
| 512 | WP699 | Aflatoxin B1 metabolism | 553 | WP699 | 7 | 0.43 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 513 | WP702 | Metapathway biotransformation Phase I and II | 554 | WP702 | 188 | 0.48 | 0.133333333333333 | 0.188888888888889 | 2.4987918295779e-23 | 0.999852323093054 |
| 514 | WP710 | DNA Damage Response (only ATM dependent) | 558 | WP710 | 115 | 0.87 | 0.13 | 0.21 | 1.57756315705304e-09 | 0.999852323093054 |
| 515 | WP712 | Estrogen signaling pathway | 559 | WP712 | 23 | 0.91 | 0.19047619047619 | 0.333333333333333 | 1.21006371795151e-15 | 0.999852323093054 |
| 516 | WP716 | Vitamin A and Carotenoid Metabolism | 560 | WP716 | 44 | 0.5 | 0.181818181818182 | 0.272727272727273 | 9.28054409606823e-14 | 0.999852323093054 |
| 517 | WP733 | Serotonin Receptor 2 and STAT3 Signaling | 563 | WP733 | 4 | 0.75 | 0.333333333333333 | 0.333333333333333 | 0.0212542319346549 | 0.999852323093054 |
| 518 | WP75 | Toll-like Receptor Signaling Pathway | 565 | WP75 | 104 | 0.75 | 0.0897435897435897 | 0.179487179487179 | 1.55030261832076e-25 | 0.999852323093054 |
| 519 | WP78 | TCA Cycle (aka Krebs or citric acid cycle) | 566 | WP78 | 18 | 1 | 0 | 0.0555555555555556 | 0.345480440691871 | 0.999852323093054 |
| 520 | WP80 | Nucleotide GPCRs | 567 | WP80 | 11 | 0.73 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 521 | WP127 | IL-5 Signaling Pathway | 7 | WP127 | 40 | 0.95 | 0.236842105263158 | 0.263157894736842 | 1.21006371795151e-15 | 0.999852323093054 |
| 522 | WP138 | Androgen receptor signaling pathway | 11 | WP138 | 91 | 0.9 | 0.195121951219512 | 0.25609756097561 | 1.33825325438479e-13 | 0.999852323093054 |
| 523 | WP1425 | Bone Morphogenic Protein (BMP) Signalling and Regulation | 16 | WP1425 | 12 | 0.83 | 0.1 | 0.2 | 0.0044135122745415 | 0.999852323093054 |
| 524 | WP1559 | TFs Regulate miRNAs related to cardiac hypertrophy | 34 | WP1559 | 12 | 0.58 | 0 | 0.142857142857143 | 0.452666162731714 | 0.999852323093054 |
| 525 | WP1946 | Cori Cycle | 53 | WP1946 | 17 | 0.82 | 0.142857142857143 | 0.142857142857143 | 7.99040804992212e-20 | 0.999852323093054 |
| 526 | WP2034 | Leptin signaling pathway | 69 | WP2034 | 76 | 0.99 | 0.213333333333333 | 0.266666666666667 | 6.63243812483213e-11 | 0.999852323093054 |
| 527 | WP2290 | RalA downstream regulated genes | 91 | WP2290 | 12 | 0.92 | 0.181818181818182 | 0.181818181818182 | 1.57756315705304e-09 | 0.999852323093054 |
| 528 | WP23 | B Cell Receptor Signaling Pathway | 93 | WP23 | 98 | 0.94 | 0.184782608695652 | 0.260869565217391 | 1.45750470372243e-17 | 0.999852323093054 |
| 529 | WP2328 | Allograft Rejection | 96 | WP2328 | 90 | 0.69 | 0.17741935483871 | 0.209677419354839 | 2.86780567028817e-25 | 0.999852323093054 |
| 530 | WP2332 | Interleukin-11 Signaling Pathway | 97 | WP2332 | 44 | 0.91 | 0.225 | 0.25 | 3.51846221320189e-12 | 0.999852323093054 |
| 531 | WP2795 | Cardiac Hypertrophic Response | 149 | WP2795 | 57 | 0.89 | 0.196078431372549 | 0.254901960784314 | 2.08918249834541e-15 | 0.999852323093054 |
| 532 | WP3614 | Photodynamic therapy-induced HIF-1 survival signaling | 233 | WP3614 | 37 | 0.89 | 0.181818181818182 | 0.242424242424242 | 3.51846221320189e-12 | 0.999852323093054 |
| 533 | WP3891 | Benzene metabolism | 287 | WP3891 | 6 | 0.5 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 534 | WP3915 | Angiopoietin Like Protein 8 Regulatory Pathway | 291 | WP3915 | 132 | 0.89 | 0.136752136752137 | 0.170940170940171 | 7.99040804992212e-20 | 0.999852323093054 |
| 535 | WP3926 | ApoE and miR-146 in inflammation and atherosclerosis | 294 | WP3926 | 9 | 0.89 | 0 | 0.125 | 0.114048118916392 | 0.999852323093054 |
| 536 | WP404 | Nucleotide Metabolism | 333 | WP404 | 19 | 0.95 | 0.166666666666667 | 0.166666666666667 | 3.57124737003596e-13 | 0.999852323093054 |
| 537 | WP4216 | Chromosomal and microsatellite instability in colorectal cancer | 362 | WP4216 | 74 | 0.96 | 0.211267605633803 | 0.267605633802817 | 1.47923810515956e-16 | 0.999852323093054 |
| 538 | WP4269 | Ethanol metabolism resulting in production of ROS by CYP2E1 | 382 | WP4269 | 10 | 0.9 | 0.111111111111111 | 0.333333333333333 | 7.45368111307164e-07 | 0.999852323093054 |
| 539 | WP4288 | MTHFR deficiency | 387 | WP4288 | 27 | 0.7 | 0.315789473684211 | 0.315789473684211 | 1.69249742410717e-08 | 0.999852323093054 |
| 540 | WP4301 | Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells | 396 | WP4301 | 18 | 1 | 0.166666666666667 | 0.222222222222222 | 9.01134422889796e-05 | 0.999852323093054 |
| 541 | WP4324 | Mitochondrial complex I assembly model OXPHOS system | 402 | WP4324 | 56 | 0.8 | 0 | 0.0222222222222222 | 0.0626324188453113 | 0.999852323093054 |
| 542 | WP4329 | miRNAs involvement in the immune response in sepsis | 403 | WP4329 | 64 | 0.5 | 0.0625 | 0.1875 | 1.55030261832076e-25 | 0.999852323093054 |
| 543 | WP438 | Non-homologous end joining | 412 | WP438 | 11 | 0.91 | 0.1 | 0.1 | 0.00934439177317729 | 0.999852323093054 |
| 544 | WP4495 | IL-10 Anti-inflammatory Signaling Pathway | 428 | WP4495 | 12 | 0.92 | 0.181818181818182 | 0.272727272727273 | 1.55030261832076e-25 | 0.999852323093054 |
| 545 | WP4507 | Molybdenum cofactor (Moco) biosynthesis | 433 | WP4507 | 7 | 1 | 0.142857142857143 | 0.285714285714286 | 3.39506009152496e-24 | 0.999852323093054 |
| 546 | WP4534 | Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms | 443 | WP4534 | 48 | 0.92 | 0.159090909090909 | 0.272727272727273 | 8.80436312071741e-23 | 0.999852323093054 |
| 547 | WP4558 | Overview of interferons-mediated signaling pathway | 456 | WP4558 | 37 | 0.38 | 0.214285714285714 | 0.214285714285714 | 0.000341914298724229 | 0.999852323093054 |
| 548 | WP4566 | Translation inhibitors in chronically activated PDGFRA cells | 463 | WP4566 | 48 | 0.94 | 0.177777777777778 | 0.2 | 8.56966962716958e-10 | 0.999852323093054 |
| 549 | WP4582 | Cancer immunotherapy by CTLA4 blockade | 466 | WP4582 | 15 | 0.8 | 0 | 0 | 0.835939678356078 | 0.999852323093054 |
| 550 | WP4656 | Joubert Syndrome | 476 | WP4656 | 77 | 0.9 | 0.130434782608696 | 0.217391304347826 | 4.67701164770016e-10 | 0.999852323093054 |
| 551 | WP501 | GPCRs, Class C Metabotropic glutamate, pheromone | 517 | WP501 | 16 | 0.31 | 0 | 0 | 0.999852323093054 | 0.999852323093054 |
| 552 | WP619 | Type II interferon signaling (IFNG) | 539 | WP619 | 37 | 0.84 | 0.193548387096774 | 0.258064516129032 | 9.44618578094348e-09 | 0.999852323093054 |
| 553 | WP69 | T-Cell antigen Receptor (TCR) Signaling Pathway | 545 | WP69 | 91 | 0.9 | 0.0975609756097561 | 0.182926829268293 | 1.55030261832076e-25 | 0.999852323093054 |
| 554 | WP691 | Tamoxifen metabolism | 547 | WP691 | 21 | 0.24 | 0.2 | 0.2 | 0.0372370714105519 | 0.999852323093054 |
| 555 | WP732 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | 562 | WP732 | 20 | 0.75 | 0.2 | 0.266666666666667 | 6.52294438984146e-17 | 0.999852323093054 |
| 556 | WP1981 | Thyroxine (Thyroid Hormone) Production | 57 | WP1981 | 6 | 0 | NA | NA | NA | NA |
| 557 | WP2491 | Diclofenac Metabolic Pathway | 123 | WP2491 | 4 | 0 | NA | NA | NA | NA |
| 558 | WP2536 | Colchicine Metabolic Pathway | 131 | WP2536 | 1 | 0 | NA | NA | NA | NA |
| 559 | WP2596 | Gastric acid production | 137 | WP2596 | 7 | 0 | NA | NA | NA | NA |
| 560 | WP2597 | Secretion of Hydrochloric Acid in Parietal Cells | 138 | WP2597 | 5 | 0 | NA | NA | NA | NA |
| 561 | WP2640 | Aripiprazole Metabolic Pathway | 143 | WP2640 | 2 | 0 | NA | NA | NA | NA |
| 562 | WP2646 | Lidocaine metabolism | 146 | WP2646 | 2 | 0 | NA | NA | NA | NA |
| 563 | WP2816 | Felbamate Metabolism | 156 | WP2816 | 2 | 0 | NA | NA | NA | NA |
| 564 | WP3627 | Gut-Liver Indole Metabolism | 236 | WP3627 | 1 | 0 | NA | NA | NA | NA |
| 565 | WP3666 | Metabolism of Dichloroethylene by CYP450 | 254 | WP3666 | 1 | 0 | NA | NA | NA | NA |
| 566 | WP4174 | Metabolism of Tetrahydrocannabinol (THC) | 351 | WP4174 | 2 | 0 | NA | NA | NA | NA |
| 567 | WP4194 | Hormonal control of Pubertal Growth Spurt | 355 | WP4194 | 2 | 0 | NA | NA | NA | NA |
| 568 | WP4233 | Acrylamide Biotransformation and Exposure Biomarkers | 371 | WP4233 | 1 | 0 | NA | NA | NA | NA |
| 569 | WP661 | Glucose Homeostasis | 541 | WP661 | 1 | 0 | NA | NA | NA | NA |